<html>
    <head>
        <meta charset="utf-8">
        
            <script src="lib/bindings/utils.js"></script>
            <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/vis-network/9.1.2/dist/dist/vis-network.min.css" integrity="sha512-WgxfT5LWjfszlPHXRmBWHkV2eceiWTOBvrKCNbdgDYTHrT2AeLCGbF4sZlZw3UMN3WtL0tGUoIAKsu8mllg/XA==" crossorigin="anonymous" referrerpolicy="no-referrer" />
            <script src="https://cdnjs.cloudflare.com/ajax/libs/vis-network/9.1.2/dist/vis-network.min.js" integrity="sha512-LnvoEWDFrqGHlHmDD2101OrLcbsfkrzoSpvtSQtxK3RMnRV0eOkhhBN2dXHKRrUU8p2DGRTk35n4O8nWSVe1mQ==" crossorigin="anonymous" referrerpolicy="no-referrer"></script>
            
        
<center>
<h1></h1>
</center>

<!-- <link rel="stylesheet" href="../node_modules/vis/dist/vis.min.css" type="text/css" />
<script type="text/javascript" src="../node_modules/vis/dist/vis.js"> </script>-->
        <link
          href="https://cdn.jsdelivr.net/npm/bootstrap@5.0.0-beta3/dist/css/bootstrap.min.css"
          rel="stylesheet"
          integrity="sha384-eOJMYsd53ii+scO/bJGFsiCZc+5NDVN2yr8+0RDqr0Ql0h+rP48ckxlpbzKgwra6"
          crossorigin="anonymous"
        />
        <script
          src="https://cdn.jsdelivr.net/npm/bootstrap@5.0.0-beta3/dist/js/bootstrap.bundle.min.js"
          integrity="sha384-JEW9xMcG8R+pH31jmWH6WWP0WintQrMb4s7ZOdauHnUtxwoG2vI5DkLtS3qm9Ekf"
          crossorigin="anonymous"
        ></script>


        <center>
          <h1></h1>
        </center>
        <style type="text/css">

             #mynetwork {
                 width: 100%;
                 height: 750px;
                 background-color: #ffffff;
                 border: 1px solid lightgray;
                 position: relative;
                 float: left;
             }

             
             #loadingBar {
                 position:absolute;
                 top:0px;
                 left:0px;
                 width: 100%;
                 height: 750px;
                 background-color:rgba(200,200,200,0.8);
                 -webkit-transition: all 0.5s ease;
                 -moz-transition: all 0.5s ease;
                 -ms-transition: all 0.5s ease;
                 -o-transition: all 0.5s ease;
                 transition: all 0.5s ease;
                 opacity:1;
             }

             #bar {
                 position:absolute;
                 top:0px;
                 left:0px;
                 width:20px;
                 height:20px;
                 margin:auto auto auto auto;
                 border-radius:11px;
                 border:2px solid rgba(30,30,30,0.05);
                 background: rgb(0, 173, 246); /* Old browsers */
                 box-shadow: 2px 0px 4px rgba(0,0,0,0.4);
             }

             #border {
                 position:absolute;
                 top:10px;
                 left:10px;
                 width:500px;
                 height:23px;
                 margin:auto auto auto auto;
                 box-shadow: 0px 0px 4px rgba(0,0,0,0.2);
                 border-radius:10px;
             }

             #text {
                 position:absolute;
                 top:8px;
                 left:530px;
                 width:30px;
                 height:50px;
                 margin:auto auto auto auto;
                 font-size:22px;
                 color: #000000;
             }

             div.outerBorder {
                 position:relative;
                 top:400px;
                 width:600px;
                 height:44px;
                 margin:auto auto auto auto;
                 border:8px solid rgba(0,0,0,0.1);
                 background: rgb(252,252,252); /* Old browsers */
                 background: -moz-linear-gradient(top,  rgba(252,252,252,1) 0%, rgba(237,237,237,1) 100%); /* FF3.6+ */
                 background: -webkit-gradient(linear, left top, left bottom, color-stop(0%,rgba(252,252,252,1)), color-stop(100%,rgba(237,237,237,1))); /* Chrome,Safari4+ */
                 background: -webkit-linear-gradient(top,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* Chrome10+,Safari5.1+ */
                 background: -o-linear-gradient(top,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* Opera 11.10+ */
                 background: -ms-linear-gradient(top,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* IE10+ */
                 background: linear-gradient(to bottom,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* W3C */
                 filter: progid:DXImageTransform.Microsoft.gradient( startColorstr='#fcfcfc', endColorstr='#ededed',GradientType=0 ); /* IE6-9 */
                 border-radius:72px;
                 box-shadow: 0px 0px 10px rgba(0,0,0,0.2);
             }
             

             

             
        </style>
    </head>


    <body>
        <div class="card" style="width: 100%">
            
            
            <div id="mynetwork" class="card-body"></div>
        </div>

        
            <div id="loadingBar">
              <div class="outerBorder">
                <div id="text">0%</div>
                <div id="border">
                  <div id="bar"></div>
                </div>
              </div>
            </div>
        
        

        <script type="text/javascript">

              // initialize global variables.
              var edges;
              var nodes;
              var allNodes;
              var allEdges;
              var nodeColors;
              var originalNodes;
              var network;
              var container;
              var options, data;
              var filter = {
                  item : '',
                  property : '',
                  value : []
              };

              

              

              // This method is responsible for drawing the graph, returns the drawn network
              function drawGraph() {
                  var container = document.getElementById('mynetwork');

                  

                  // parsing and collecting nodes and edges from the python
                  nodes = new vis.DataSet([{"color": "#97c2fc", "id": "NCT03821493", "label": "NCT03821493", "shape": "dot", "title": "SubjectNode: NCT03821493"}, {"color": "#97c2fc", "id": "Advanced Solid Malignancies", "label": "Advanced Solid Malignancies", "shape": "dot", "title": "ObjectNode: Advanced Solid Malignancies"}, {"color": "#97c2fc", "id": "Hepatitis B e Antigen Seroconversion", "label": "Hepatitis B e Antigen Seroconversion", "shape": "dot", "title": "ObjectNode: Hepatitis B e Antigen Seroconversion"}, {"color": "#97c2fc", "id": "hypersensitivity itraconazole", "label": "hypersensitivity itraconazole", "shape": "dot", "title": "ObjectNode: hypersensitivity itraconazole"}, {"color": "#97c2fc", "id": "diagnosed chronic heart failure", "label": "diagnosed chronic heart failure", "shape": "dot", "title": "ObjectNode: diagnosed chronic heart failure"}, {"color": "#97c2fc", "id": "Body weight \u2265 45 kg", "label": "Body weight \u2265 45 kg", "shape": "dot", "title": "ObjectNode: Body weight \u2265 45 kg"}, {"color": "#97c2fc", "id": "BMI 18 to 32 kg/m2", "label": "BMI 18 to 32 kg/m2", "shape": "dot", "title": "ObjectNode: BMI 18 to 32 kg/m2"}, {"color": "#97c2fc", "id": "Maximum Observed Plasma Analyte Concentration", "label": "Maximum Observed Plasma Analyte Concentration", "shape": "dot", "title": "ObjectNode: Maximum Observed Plasma Analyte Concentration"}, {"color": "#97c2fc", "id": "AUCinf of PF-06835919", "label": "AUCinf of PF-06835919", "shape": "dot", "title": "ObjectNode: AUCinf of PF-06835919"}, {"color": "#97c2fc", "id": "Isavuconazole", "label": "Isavuconazole", "shape": "dot", "title": "ObjectNode: Isavuconazole"}, {"color": "#97c2fc", "id": "Healthy Fed Participants", "label": "Healthy Fed Participants", "shape": "dot", "title": "ObjectNode: Healthy Fed Participants"}, {"color": "#97c2fc", "id": "NCT04544293", "label": "NCT04544293", "shape": "dot", "title": "SubjectNode: NCT04544293"}, {"color": "#97c2fc", "id": "Baseline to Week 49", "label": "Baseline to Week 49", "shape": "dot", "title": "ObjectNode: Baseline to Week 49"}, {"color": "#97c2fc", "id": "Baseline to 28 days", "label": "Baseline to 28 days", "shape": "dot", "title": "ObjectNode: Baseline to 28 days"}, {"color": "#97c2fc", "id": "SGRQ Activity component score", "label": "SGRQ Activity component score", "shape": "dot", "title": "ObjectNode: SGRQ Activity component score"}, {"color": "#97c2fc", "id": "St. George\u0027s Hospital Respiratory Questionnaire", "label": "St. George\u0027s Hospital Respiratory Questionnaire", "shape": "dot", "title": "ObjectNode: St. George\u0027s Hospital Respiratory Questionnaire"}, {"color": "#97c2fc", "id": "Change from baseline in Peak FEV1 response", "label": "Change from baseline in Peak FEV1 response", "shape": "dot", "title": "ObjectNode: Change from baseline in Peak FEV1 response"}, {"color": "#97c2fc", "id": "Inhaled Molgramostim Nebulizer Solution", "label": "Inhaled Molgramostim Nebulizer Solution", "shape": "dot", "title": "ObjectNode: Inhaled Molgramostim Nebulizer Solution"}, {"color": "#97c2fc", "id": "Idiopathic Pulmonary Fibrosis", "label": "Idiopathic Pulmonary Fibrosis", "shape": "dot", "title": "ObjectNode: Idiopathic Pulmonary Fibrosis"}, {"color": "#97c2fc", "id": "NCT03181893", "label": "NCT03181893", "shape": "dot", "title": "SubjectNode: NCT03181893"}, {"color": "#97c2fc", "id": "Treatment-Emergent SAEs", "label": "Treatment-Emergent SAEs", "shape": "dot", "title": "ObjectNode: Treatment-Emergent SAEs"}, {"color": "#97c2fc", "id": "CDASI score change", "label": "CDASI score change", "shape": "dot", "title": "ObjectNode: CDASI score change"}, {"color": "#97c2fc", "id": "Intravenous Sabirnetug", "label": "Intravenous Sabirnetug", "shape": "dot", "title": "ObjectNode: Intravenous Sabirnetug"}, {"color": "#97c2fc", "id": "Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score", "label": "Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score", "shape": "dot", "title": "ObjectNode: Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score"}, {"color": "#97c2fc", "id": "NCT01328093", "label": "NCT01328093", "shape": "dot", "title": "SubjectNode: NCT01328093"}, {"color": "#97c2fc", "id": "Baseline condition", "label": "Baseline condition", "shape": "dot", "title": "ObjectNode: Baseline condition"}, {"color": "#97c2fc", "id": "Simpson Angus Rating Scale", "label": "Simpson Angus Rating Scale", "shape": "dot", "title": "ObjectNode: Simpson Angus Rating Scale"}, {"color": "#97c2fc", "id": "Barnes Akathisia Rating Scale", "label": "Barnes Akathisia Rating Scale", "shape": "dot", "title": "ObjectNode: Barnes Akathisia Rating Scale"}, {"color": "#97c2fc", "id": "Change in weight control", "label": "Change in weight control", "shape": "dot", "title": "ObjectNode: Change in weight control"}, {"color": "#97c2fc", "id": "Iloperidone", "label": "Iloperidone", "shape": "dot", "title": "ObjectNode: Iloperidone"}, {"color": "#97c2fc", "id": "LY2624803", "label": "LY2624803", "shape": "dot", "title": "ObjectNode: LY2624803"}, {"color": "#97c2fc", "id": "Early-Episode Schizophrenia", "label": "Early-Episode Schizophrenia", "shape": "dot", "title": "ObjectNode: Early-Episode Schizophrenia"}, {"color": "#97c2fc", "id": "NCT04732793", "label": "NCT04732793", "shape": "dot", "title": "SubjectNode: NCT04732793"}, {"color": "#97c2fc", "id": "WOMAC A", "label": "WOMAC A", "shape": "dot", "title": "ObjectNode: WOMAC A"}, {"color": "#97c2fc", "id": "baseline through 16 weeks", "label": "baseline through 16 weeks", "shape": "dot", "title": "ObjectNode: baseline through 16 weeks"}, {"color": "#97c2fc", "id": "WOMAC B Stiffness", "label": "WOMAC B Stiffness", "shape": "dot", "title": "ObjectNode: WOMAC B Stiffness"}, {"color": "#97c2fc", "id": "WOMAC A subscale", "label": "WOMAC A subscale", "shape": "dot", "title": "ObjectNode: WOMAC A subscale"}, {"color": "#97c2fc", "id": "Hyruan ONE", "label": "Hyruan ONE", "shape": "dot", "title": "ObjectNode: Hyruan ONE"}, {"color": "#97c2fc", "id": "Osteoarthritis-related Pain", "label": "Osteoarthritis-related Pain", "shape": "dot", "title": "ObjectNode: Osteoarthritis-related Pain"}, {"color": "#97c2fc", "id": "NCT02240693", "label": "NCT02240693", "shape": "dot", "title": "SubjectNode: NCT02240693"}, {"color": "#97c2fc", "id": "Change From Baseline-2", "label": "Change From Baseline-2", "shape": "dot", "title": "ObjectNode: Change From Baseline-2"}, {"color": "#97c2fc", "id": "Early Symptomatic Alzheimer\u0027s Disease", "label": "Early Symptomatic Alzheimer\u0027s Disease", "shape": "dot", "title": "ObjectNode: Early Symptomatic Alzheimer\u0027s Disease"}, {"color": "#97c2fc", "id": "BI 456906", "label": "BI 456906", "shape": "dot", "title": "ObjectNode: BI 456906"}, {"color": "#97c2fc", "id": "self care and daily function", "label": "self care and daily function", "shape": "dot", "title": "ObjectNode: self care and daily function"}, {"color": "#97c2fc", "id": "ADCS-ADL scale", "label": "ADCS-ADL scale", "shape": "dot", "title": "ObjectNode: ADCS-ADL scale"}, {"color": "#97c2fc", "id": "NCT06456593", "label": "NCT06456593", "shape": "dot", "title": "SubjectNode: NCT06456593"}, {"color": "#97c2fc", "id": "SES-CD ulcer subscore \u003e 1", "label": "SES-CD ulcer subscore \u003e 1", "shape": "dot", "title": "ObjectNode: SES-CD ulcer subscore \u003e 1"}, {"color": "#97c2fc", "id": "endoscopic treatment improvement", "label": "endoscopic treatment improvement", "shape": "dot", "title": "ObjectNode: endoscopic treatment improvement"}, {"color": "#97c2fc", "id": "Clinically Significant Remission", "label": "Clinically Significant Remission", "shape": "dot", "title": "ObjectNode: Clinically Significant Remission"}, {"color": "#97c2fc", "id": "CDAI-Defined Clinical Response", "label": "CDAI-Defined Clinical Response", "shape": "dot", "title": "ObjectNode: CDAI-Defined Clinical Response"}, {"color": "#97c2fc", "id": "Weeks 12", "label": "Weeks 12", "shape": "dot", "title": "ObjectNode: Weeks 12"}, {"color": "#97c2fc", "id": "Week 60", "label": "Week 60", "shape": "dot", "title": "ObjectNode: Week 60"}, {"color": "#97c2fc", "id": "Obefazimod", "label": "Obefazimod", "shape": "dot", "title": "ObjectNode: Obefazimod"}, {"color": "#97c2fc", "id": "PRO-2 Remission", "label": "PRO-2 Remission", "shape": "dot", "title": "ObjectNode: PRO-2 Remission"}, {"color": "#97c2fc", "id": "Mayo IBD symptom severity score", "label": "Mayo IBD symptom severity score", "shape": "dot", "title": "ObjectNode: Mayo IBD symptom severity score"}, {"color": "#97c2fc", "id": "Simple Endoscopic Score for Crohn\u0027s disease (SES-CD)", "label": "Simple Endoscopic Score for Crohn\u0027s disease (SES-CD)", "shape": "dot", "title": "ObjectNode: Simple Endoscopic Score for Crohn\u0027s disease (SES-CD)"}, {"color": "#97c2fc", "id": "Immune-related Colitis", "label": "Immune-related Colitis", "shape": "dot", "title": "ObjectNode: Immune-related Colitis"}, {"color": "#97c2fc", "id": "NCT05590793", "label": "NCT05590793", "shape": "dot", "title": "SubjectNode: NCT05590793"}, {"color": "#97c2fc", "id": "Change in electrocardiograms", "label": "Change in electrocardiograms", "shape": "dot", "title": "ObjectNode: Change in electrocardiograms"}, {"color": "#97c2fc", "id": "Serum Testosterone Levels", "label": "Serum Testosterone Levels", "shape": "dot", "title": "ObjectNode: Serum Testosterone Levels"}, {"color": "#97c2fc", "id": "Triptorelin Pamoate PR 3-month", "label": "Triptorelin Pamoate PR 3-month", "shape": "dot", "title": "ObjectNode: Triptorelin Pamoate PR 3-month"}, {"color": "#97c2fc", "id": "Chinese Adult Subjects", "label": "Chinese Adult Subjects", "shape": "dot", "title": "ObjectNode: Chinese Adult Subjects"}, {"color": "#97c2fc", "id": "Advanced Prostate Cancer", "label": "Advanced Prostate Cancer", "shape": "dot", "title": "ObjectNode: Advanced Prostate Cancer"}, {"color": "#97c2fc", "id": "physical examination results", "label": "physical examination results", "shape": "dot", "title": "ObjectNode: physical examination results"}, {"color": "#97c2fc", "id": "Prostate-Specific Antigen Levels", "label": "Prostate-Specific Antigen Levels", "shape": "dot", "title": "ObjectNode: Prostate-Specific Antigen Levels"}, {"color": "#97c2fc", "id": "Clinically significant abnormalities in vital signs", "label": "Clinically significant abnormalities in vital signs", "shape": "dot", "title": "ObjectNode: Clinically significant abnormalities in vital signs"}, {"color": "#97c2fc", "id": "Screening laboratory parameters", "label": "Screening laboratory parameters", "shape": "dot", "title": "ObjectNode: Screening laboratory parameters"}, {"color": "#97c2fc", "id": "NCT05732454", "label": "NCT05732454", "shape": "dot", "title": "SubjectNode: NCT05732454"}, {"color": "#97c2fc", "id": "Overall platelet response", "label": "Overall platelet response", "shape": "dot", "title": "ObjectNode: Overall platelet response"}, {"color": "#97c2fc", "id": "RBC", "label": "RBC", "shape": "dot", "title": "ObjectNode: RBC"}, {"color": "#97c2fc", "id": "IGA cleared or minimal", "label": "IGA cleared or minimal", "shape": "dot", "title": "ObjectNode: IGA cleared or minimal"}, {"color": "#97c2fc", "id": "Urea Nitrogen", "label": "Urea Nitrogen", "shape": "dot", "title": "ObjectNode: Urea Nitrogen"}, {"color": "#97c2fc", "id": "oral medications", "label": "oral medications", "shape": "dot", "title": "ObjectNode: oral medications"}, {"color": "#97c2fc", "id": "Mean Change Total Bilirubin", "label": "Mean Change Total Bilirubin", "shape": "dot", "title": "ObjectNode: Mean Change Total Bilirubin"}, {"color": "#97c2fc", "id": "mean corpuscular hemoglobin", "label": "mean corpuscular hemoglobin", "shape": "dot", "title": "ObjectNode: mean corpuscular hemoglobin"}, {"color": "#97c2fc", "id": "TBNK panel", "label": "TBNK panel", "shape": "dot", "title": "ObjectNode: TBNK panel"}, {"color": "#97c2fc", "id": "WBC", "label": "WBC", "shape": "dot", "title": "ObjectNode: WBC"}, {"color": "#97c2fc", "id": "Children with atopic dermatitis", "label": "Children with atopic dermatitis", "shape": "dot", "title": "ObjectNode: Children with atopic dermatitis"}, {"color": "#97c2fc", "id": "Oral Etrasimod", "label": "Oral Etrasimod", "shape": "dot", "title": "ObjectNode: Oral Etrasimod"}, {"color": "#97c2fc", "id": "Serum creatinine \u22643 mg/dL", "label": "Serum creatinine \u22643 mg/dL", "shape": "dot", "title": "ObjectNode: Serum creatinine \u22643 mg/dL"}, {"color": "#97c2fc", "id": "Hematocrit change", "label": "Hematocrit change", "shape": "dot", "title": "ObjectNode: Hematocrit change"}, {"color": "#97c2fc", "id": "NCT02220933", "label": "NCT02220933", "shape": "dot", "title": "SubjectNode: NCT02220933"}, {"color": "#97c2fc", "id": "EDSS or TW25", "label": "EDSS or TW25", "shape": "dot", "title": "ObjectNode: EDSS or TW25"}, {"color": "#97c2fc", "id": "Disease duration of secondary progressive multiple sclerosis", "label": "Disease duration of secondary progressive multiple sclerosis", "shape": "dot", "title": "ObjectNode: Disease duration of secondary progressive multiple sclerosis"}, {"color": "#97c2fc", "id": "MSWS", "label": "MSWS", "shape": "dot", "title": "ObjectNode: MSWS"}, {"color": "#97c2fc", "id": "MD1003", "label": "MD1003", "shape": "dot", "title": "ObjectNode: MD1003"}, {"color": "#97c2fc", "id": "decreased EDSS", "label": "decreased EDSS", "shape": "dot", "title": "ObjectNode: decreased EDSS"}, {"color": "#97c2fc", "id": "NCT03836287", "label": "NCT03836287", "shape": "dot", "title": "SubjectNode: NCT03836287"}, {"color": "#97c2fc", "id": "Hyperhidrosis severity 3 or 4", "label": "Hyperhidrosis severity 3 or 4", "shape": "dot", "title": "ObjectNode: Hyperhidrosis severity 3 or 4"}, {"color": "#97c2fc", "id": "Sofpironium Bromide Gel", "label": "Sofpironium Bromide Gel", "shape": "dot", "title": "ObjectNode: Sofpironium Bromide Gel"}, {"color": "#97c2fc", "id": "Gravimetrically Measured Sweat Production", "label": "Gravimetrically Measured Sweat Production", "shape": "dot", "title": "ObjectNode: Gravimetrically Measured Sweat Production"}, {"color": "#97c2fc", "id": "Primary Axillary Hyperhidrosis", "label": "Primary Axillary Hyperhidrosis", "shape": "dot", "title": "ObjectNode: Primary Axillary Hyperhidrosis"}, {"color": "#97c2fc", "id": "Up to 32 weeks", "label": "Up to 32 weeks", "shape": "dot", "title": "ObjectNode: Up to 32 weeks"}, {"color": "#97c2fc", "id": "NCT03068754", "label": "NCT03068754", "shape": "dot", "title": "SubjectNode: NCT03068754"}, {"color": "#97c2fc", "id": "Clinically Significant Response", "label": "Clinically Significant Response", "shape": "dot", "title": "ObjectNode: Clinically Significant Response"}, {"color": "#97c2fc", "id": "Lung function parameters", "label": "Lung function parameters", "shape": "dot", "title": "ObjectNode: Lung function parameters"}, {"color": "#97c2fc", "id": "Acthar Gel", "label": "Acthar Gel", "shape": "dot", "title": "ObjectNode: Acthar Gel"}, {"color": "#97c2fc", "id": "Rasch Overall ALS Disability Scale", "label": "Rasch Overall ALS Disability Scale", "shape": "dot", "title": "ObjectNode: Rasch Overall ALS Disability Scale"}, {"color": "#97c2fc", "id": "ALS or MS", "label": "ALS or MS", "shape": "dot", "title": "ObjectNode: ALS or MS"}, {"color": "#97c2fc", "id": "NCT06272487", "label": "NCT06272487", "shape": "dot", "title": "SubjectNode: NCT06272487"}, {"color": "#97c2fc", "id": "Diagnosis of severe hypertension", "label": "Diagnosis of severe hypertension", "shape": "dot", "title": "ObjectNode: Diagnosis of severe hypertension"}, {"color": "#97c2fc", "id": "Zilebesiran", "label": "Zilebesiran", "shape": "dot", "title": "ObjectNode: Zilebesiran"}, {"color": "#97c2fc", "id": "Standard of Care", "label": "Standard of Care", "shape": "dot", "title": "ObjectNode: Standard of Care"}, {"color": "#97c2fc", "id": "Percent Change from Baseline in Serum Angiotensinogen", "label": "Percent Change from Baseline in Serum Angiotensinogen", "shape": "dot", "title": "ObjectNode: Percent Change from Baseline in Serum Angiotensinogen"}, {"color": "#97c2fc", "id": "NCT02438787", "label": "NCT02438787", "shape": "dot", "title": "SubjectNode: NCT02438787"}, {"color": "#97c2fc", "id": "ASAS20 treatment response", "label": "ASAS20 treatment response", "shape": "dot", "title": "ObjectNode: ASAS20 treatment response"}, {"color": "#97c2fc", "id": "Prior Anti-TNF Therapy", "label": "Prior Anti-TNF Therapy", "shape": "dot", "title": "ObjectNode: Prior Anti-TNF Therapy"}, {"color": "#97c2fc", "id": "Early Spondyloarthritis", "label": "Early Spondyloarthritis", "shape": "dot", "title": "ObjectNode: Early Spondyloarthritis"}, {"color": "#97c2fc", "id": "Abrilumab", "label": "Abrilumab", "shape": "dot", "title": "ObjectNode: Abrilumab"}, {"color": "#97c2fc", "id": "ASAS40 treatment response", "label": "ASAS40 treatment response", "shape": "dot", "title": "ObjectNode: ASAS40 treatment response"}, {"color": "#97c2fc", "id": "NCT04053387", "label": "NCT04053387", "shape": "dot", "title": "SubjectNode: NCT04053387"}, {"color": "#97c2fc", "id": "Median Time to Improvement", "label": "Median Time to Improvement", "shape": "dot", "title": "ObjectNode: Median Time to Improvement"}, {"color": "#97c2fc", "id": "at least one psoriatic plaque", "label": "at least one psoriatic plaque", "shape": "dot", "title": "ObjectNode: at least one psoriatic plaque"}, {"color": "#97c2fc", "id": "sPGA (0)", "label": "sPGA (0)", "shape": "dot", "title": "ObjectNode: sPGA (0)"}, {"color": "#97c2fc", "id": "VTAMA (Tapinarof) Cream", "label": "VTAMA (Tapinarof) Cream", "shape": "dot", "title": "ObjectNode: VTAMA (Tapinarof) Cream"}, {"color": "#97c2fc", "id": "Potentially Clinically Important Changes", "label": "Potentially Clinically Important Changes", "shape": "dot", "title": "ObjectNode: Potentially Clinically Important Changes"}, {"color": "#97c2fc", "id": "NCT05002933", "label": "NCT05002933", "shape": "dot", "title": "SubjectNode: NCT05002933"}, {"color": "#97c2fc", "id": "Adults \u003e=12 years old", "label": "Adults \u003e=12 years old", "shape": "dot", "title": "ObjectNode: Adults \u003e=12 years old"}, {"color": "#97c2fc", "id": "Overweight and Obese Subjects With Type 2 Diabetes", "label": "Overweight and Obese Subjects With Type 2 Diabetes", "shape": "dot", "title": "ObjectNode: Overweight and Obese Subjects With Type 2 Diabetes"}, {"color": "#97c2fc", "id": "Percentage of Participants Achieving a Therapeutic Glycemic Response", "label": "Percentage of Participants Achieving a Therapeutic Glycemic Response", "shape": "dot", "title": "ObjectNode: Percentage of Participants Achieving a Therapeutic Glycemic Response"}, {"color": "#97c2fc", "id": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "label": "Insulin Glargine/Lixisenatide Fixed Ratio Combination", "shape": "dot", "title": "ObjectNode: Insulin Glargine/Lixisenatide Fixed Ratio Combination"}, {"color": "#97c2fc", "id": "Adjusted Mean Change HbA1c", "label": "Adjusted Mean Change HbA1c", "shape": "dot", "title": "ObjectNode: Adjusted Mean Change HbA1c"}, {"color": "#97c2fc", "id": "NCT05426733", "label": "NCT05426733", "shape": "dot", "title": "SubjectNode: NCT05426733"}, {"color": "#97c2fc", "id": "Change mid-arm circumference", "label": "Change mid-arm circumference", "shape": "dot", "title": "ObjectNode: Change mid-arm circumference"}, {"color": "#97c2fc", "id": "Change serum bile acids", "label": "Change serum bile acids", "shape": "dot", "title": "ObjectNode: Change serum bile acids"}, {"color": "#97c2fc", "id": "Primary Biliary Cholangitis", "label": "Primary Biliary Cholangitis", "shape": "dot", "title": "ObjectNode: Primary Biliary Cholangitis"}, {"color": "#97c2fc", "id": "Odevixibat", "label": "Odevixibat", "shape": "dot", "title": "ObjectNode: Odevixibat"}, {"color": "#97c2fc", "id": "Change in Fibrosis-4 (FIB-4) Score", "label": "Change in Fibrosis-4 (FIB-4) Score", "shape": "dot", "title": "ObjectNode: Change in Fibrosis-4 (FIB-4) Score"}, {"color": "#97c2fc", "id": "Change pediatric end-stage liver disease score", "label": "Change pediatric end-stage liver disease score", "shape": "dot", "title": "ObjectNode: Change pediatric end-stage liver disease score"}, {"color": "#97c2fc", "id": "Change AST to platelet ratio index", "label": "Change AST to platelet ratio index", "shape": "dot", "title": "ObjectNode: Change AST to platelet ratio index"}, {"color": "#97c2fc", "id": "Proportion alive", "label": "Proportion alive", "shape": "dot", "title": "ObjectNode: Proportion alive"}, {"color": "#97c2fc", "id": "Completion of 104-week Treatment Period", "label": "Completion of 104-week Treatment Period", "shape": "dot", "title": "ObjectNode: Completion of 104-week Treatment Period"}, {"color": "#97c2fc", "id": "Patient\u0027s written informed consent", "label": "Patient\u0027s written informed consent", "shape": "dot", "title": "ObjectNode: Patient\u0027s written informed consent"}, {"color": "#97c2fc", "id": "Change height", "label": "Change height", "shape": "dot", "title": "ObjectNode: Change height"}, {"color": "#97c2fc", "id": "Time to onset sentinel events", "label": "Time to onset sentinel events", "shape": "dot", "title": "ObjectNode: Time to onset sentinel events"}, {"color": "#97c2fc", "id": "NCT04437433", "label": "NCT04437433", "shape": "dot", "title": "SubjectNode: NCT04437433"}, {"color": "#97c2fc", "id": "Columbia Suicide Severity Rating Scale", "label": "Columbia Suicide Severity Rating Scale", "shape": "dot", "title": "ObjectNode: Columbia Suicide Severity Rating Scale"}, {"color": "#97c2fc", "id": "Number of patients with clinically significant changes in vital signs", "label": "Number of patients with clinically significant changes in vital signs", "shape": "dot", "title": "ObjectNode: Number of patients with clinically significant changes in vital signs"}, {"color": "#97c2fc", "id": "Migraine Headaches", "label": "Migraine Headaches", "shape": "dot", "title": "ObjectNode: Migraine Headaches"}, {"color": "#97c2fc", "id": "Clinically significant abnormalities in clinical laboratory values", "label": "Clinically significant abnormalities in clinical laboratory values", "shape": "dot", "title": "ObjectNode: Clinically significant abnormalities in clinical laboratory values"}, {"color": "#97c2fc", "id": "Completed all visits", "label": "Completed all visits", "shape": "dot", "title": "ObjectNode: Completed all visits"}, {"color": "#97c2fc", "id": "Oral Atogepant", "label": "Oral Atogepant", "shape": "dot", "title": "ObjectNode: Oral Atogepant"}, {"color": "#97c2fc", "id": "Clinically significant abnormalities in ECG", "label": "Clinically significant abnormalities in ECG", "shape": "dot", "title": "ObjectNode: Clinically significant abnormalities in ECG"}, {"color": "#97c2fc", "id": "NCT04479787", "label": "NCT04479787", "shape": "dot", "title": "SubjectNode: NCT04479787"}, {"color": "#97c2fc", "id": "Responder Rate PGIC", "label": "Responder Rate PGIC", "shape": "dot", "title": "ObjectNode: Responder Rate PGIC"}, {"color": "#97c2fc", "id": "NRS mean change", "label": "NRS mean change", "shape": "dot", "title": "ObjectNode: NRS mean change"}, {"color": "#97c2fc", "id": "Change in Back Pain", "label": "Change in Back Pain", "shape": "dot", "title": "ObjectNode: Change in Back Pain"}, {"color": "#97c2fc", "id": "10 kHz Spinal Cord Stimulation", "label": "10 kHz Spinal Cord Stimulation", "shape": "dot", "title": "ObjectNode: 10 kHz Spinal Cord Stimulation"}, {"color": "#97c2fc", "id": "\u2265 30% decrease from baseline", "label": "\u2265 30% decrease from baseline", "shape": "dot", "title": "ObjectNode: \u2265 30% decrease from baseline"}, {"color": "#97c2fc", "id": "Change in OSDI", "label": "Change in OSDI", "shape": "dot", "title": "ObjectNode: Change in OSDI"}, {"color": "#97c2fc", "id": "Study Composite Responder", "label": "Study Composite Responder", "shape": "dot", "title": "ObjectNode: Study Composite Responder"}, {"color": "#97c2fc", "id": "Medical Management", "label": "Medical Management", "shape": "dot", "title": "ObjectNode: Medical Management"}, {"color": "#97c2fc", "id": "NCT00327587", "label": "NCT00327587", "shape": "dot", "title": "SubjectNode: NCT00327587"}, {"color": "#97c2fc", "id": "Olmesartan and Amlodipine", "label": "Olmesartan and Amlodipine", "shape": "dot", "title": "ObjectNode: Olmesartan and Amlodipine"}, {"color": "#97c2fc", "id": "Systolic BP control", "label": "Systolic BP control", "shape": "dot", "title": "ObjectNode: Systolic BP control"}, {"color": "#97c2fc", "id": "Diastolic BP \u226590 mmHg", "label": "Diastolic BP \u226590 mmHg", "shape": "dot", "title": "ObjectNode: Diastolic BP \u226590 mmHg"}, {"color": "#97c2fc", "id": "Normalized blood pressure", "label": "Normalized blood pressure", "shape": "dot", "title": "ObjectNode: Normalized blood pressure"}, {"color": "#97c2fc", "id": "Systolic BP \u2265140 mmHg", "label": "Systolic BP \u2265140 mmHg", "shape": "dot", "title": "ObjectNode: Systolic BP \u2265140 mmHg"}, {"color": "#97c2fc", "id": "Diastolic BP \u226580 mmHg", "label": "Diastolic BP \u226580 mmHg", "shape": "dot", "title": "ObjectNode: Diastolic BP \u226580 mmHg"}, {"color": "#97c2fc", "id": "Arm circumference \u003e 42 cm", "label": "Arm circumference \u003e 42 cm", "shape": "dot", "title": "ObjectNode: Arm circumference \u003e 42 cm"}, {"color": "#97c2fc", "id": "Amlodipine Besylate/Benazepril", "label": "Amlodipine Besylate/Benazepril", "shape": "dot", "title": "ObjectNode: Amlodipine Besylate/Benazepril"}, {"color": "#97c2fc", "id": "Diastolic blood pressure \u003c 60 mm Hg", "label": "Diastolic blood pressure \u003c 60 mm Hg", "shape": "dot", "title": "ObjectNode: Diastolic blood pressure \u003c 60 mm Hg"}, {"color": "#97c2fc", "id": "HCTZ 25 mg", "label": "HCTZ 25 mg", "shape": "dot", "title": "ObjectNode: HCTZ 25 mg"}, {"color": "#97c2fc", "id": "NCT02618187", "label": "NCT02618187", "shape": "dot", "title": "SubjectNode: NCT02618187"}, {"color": "#97c2fc", "id": "Duration of Ulcerative Colitis", "label": "Duration of Ulcerative Colitis", "shape": "dot", "title": "ObjectNode: Duration of Ulcerative Colitis"}, {"color": "#97c2fc", "id": "SER-214", "label": "SER-214", "shape": "dot", "title": "ObjectNode: SER-214"}, {"color": "#97c2fc", "id": "Microbiota composition analysis", "label": "Microbiota composition analysis", "shape": "dot", "title": "ObjectNode: Microbiota composition analysis"}, {"color": "#97c2fc", "id": "Participants in Remission", "label": "Participants in Remission", "shape": "dot", "title": "ObjectNode: Participants in Remission"}, {"color": "#97c2fc", "id": "9-point modified Mayo score", "label": "9-point modified Mayo score", "shape": "dot", "title": "ObjectNode: 9-point modified Mayo score"}, {"color": "#97c2fc", "id": "NCT01429987", "label": "NCT01429987", "shape": "dot", "title": "SubjectNode: NCT01429987"}, {"color": "#97c2fc", "id": "stool frequency evaluation", "label": "stool frequency evaluation", "shape": "dot", "title": "ObjectNode: stool frequency evaluation"}, {"color": "#97c2fc", "id": "18 to 55 years old", "label": "18 to 55 years old", "shape": "dot", "title": "ObjectNode: 18 to 55 years old"}, {"color": "#97c2fc", "id": "Plecanatide", "label": "Plecanatide", "shape": "dot", "title": "ObjectNode: Plecanatide"}, {"color": "#97c2fc", "id": "12-week CSBM Frequency", "label": "12-week CSBM Frequency", "shape": "dot", "title": "ObjectNode: 12-week CSBM Frequency"}, {"color": "#97c2fc", "id": "IBS-Constipation", "label": "IBS-Constipation", "shape": "dot", "title": "ObjectNode: IBS-Constipation"}, {"color": "#97c2fc", "id": "Straining Score", "label": "Straining Score", "shape": "dot", "title": "ObjectNode: Straining Score"}, {"color": "#97c2fc", "id": "ROME IV criteria", "label": "ROME IV criteria", "shape": "dot", "title": "ObjectNode: ROME IV criteria"}, {"color": "#97c2fc", "id": "NCT04158687", "label": "NCT04158687", "shape": "dot", "title": "SubjectNode: NCT04158687"}, {"color": "#97c2fc", "id": "CP-601", "label": "CP-601", "shape": "dot", "title": "ObjectNode: CP-601"}, {"color": "#97c2fc", "id": "Total Personal and Social Performance", "label": "Total Personal and Social Performance", "shape": "dot", "title": "ObjectNode: Total Personal and Social Performance"}, {"color": "#97c2fc", "id": "CGI-Severity Score", "label": "CGI-Severity Score", "shape": "dot", "title": "ObjectNode: CGI-Severity Score"}, {"color": "#97c2fc", "id": "NCT01862887", "label": "NCT01862887", "shape": "dot", "title": "SubjectNode: NCT01862887"}, {"color": "#97c2fc", "id": "regular alcohol consumption", "label": "regular alcohol consumption", "shape": "dot", "title": "ObjectNode: regular alcohol consumption"}, {"color": "#97c2fc", "id": "clinically significant changes in Electrocardiogram readings", "label": "clinically significant changes in Electrocardiogram readings", "shape": "dot", "title": "ObjectNode: clinically significant changes in Electrocardiogram readings"}, {"color": "#97c2fc", "id": "PF-07038124", "label": "PF-07038124", "shape": "dot", "title": "ObjectNode: PF-07038124"}, {"color": "#97c2fc", "id": "Fmax", "label": "Fmax", "shape": "dot", "title": "ObjectNode: Fmax"}, {"color": "#97c2fc", "id": "Healthy adult male subjects", "label": "Healthy adult male subjects", "shape": "dot", "title": "ObjectNode: Healthy adult male subjects"}, {"color": "#97c2fc", "id": "Healthy male or female", "label": "Healthy male or female", "shape": "dot", "title": "ObjectNode: Healthy male or female"}, {"color": "#97c2fc", "id": "QTcB change", "label": "QTcB change", "shape": "dot", "title": "ObjectNode: QTcB change"}, {"color": "#97c2fc", "id": "clinically significant respiratory", "label": "clinically significant respiratory", "shape": "dot", "title": "ObjectNode: clinically significant respiratory"}, {"color": "#97c2fc", "id": "Time for Cmax", "label": "Time for Cmax", "shape": "dot", "title": "ObjectNode: Time for Cmax"}, {"color": "#97c2fc", "id": "clinically significant allergic disease", "label": "clinically significant allergic disease", "shape": "dot", "title": "ObjectNode: clinically significant allergic disease"}, {"color": "#97c2fc", "id": "severe renal involvement at Screening", "label": "severe renal involvement at Screening", "shape": "dot", "title": "ObjectNode: severe renal involvement at Screening"}, {"color": "#97c2fc", "id": "Total Fat Mass", "label": "Total Fat Mass", "shape": "dot", "title": "ObjectNode: Total Fat Mass"}, {"color": "#97c2fc", "id": "endocrine abnormalities", "label": "endocrine abnormalities", "shape": "dot", "title": "ObjectNode: endocrine abnormalities"}, {"color": "#97c2fc", "id": "psychiatric disease", "label": "psychiatric disease", "shape": "dot", "title": "ObjectNode: psychiatric disease"}, {"color": "#97c2fc", "id": "Mean change in BMI", "label": "Mean change in BMI", "shape": "dot", "title": "ObjectNode: Mean change in BMI"}, {"color": "#97c2fc", "id": "hepatic dysfunction", "label": "hepatic dysfunction", "shape": "dot", "title": "ObjectNode: hepatic dysfunction"}, {"color": "#97c2fc", "id": "neurological disorder", "label": "neurological disorder", "shape": "dot", "title": "ObjectNode: neurological disorder"}, {"color": "#97c2fc", "id": "positive urine drug screen", "label": "positive urine drug screen", "shape": "dot", "title": "ObjectNode: positive urine drug screen"}, {"color": "#97c2fc", "id": "AUC from time zero", "label": "AUC from time zero", "shape": "dot", "title": "ObjectNode: AUC from time zero"}, {"color": "#97c2fc", "id": "Clinically significant haematology assessment abnormalities", "label": "Clinically significant haematology assessment abnormalities", "shape": "dot", "title": "ObjectNode: Clinically significant haematology assessment abnormalities"}, {"color": "#97c2fc", "id": "gastrointestinal abnormalities", "label": "gastrointestinal abnormalities", "shape": "dot", "title": "ObjectNode: gastrointestinal abnormalities"}, {"color": "#97c2fc", "id": "NCT00397033", "label": "NCT00397033", "shape": "dot", "title": "SubjectNode: NCT00397033"}, {"color": "#97c2fc", "id": "PANSS General Psychopathology Subscale", "label": "PANSS General Psychopathology Subscale", "shape": "dot", "title": "ObjectNode: PANSS General Psychopathology Subscale"}, {"color": "#97c2fc", "id": "Greater Than 50% Reduction", "label": "Greater Than 50% Reduction", "shape": "dot", "title": "ObjectNode: Greater Than 50% Reduction"}, {"color": "#97c2fc", "id": "Oral Paliperidone Extended-Release", "label": "Oral Paliperidone Extended-Release", "shape": "dot", "title": "ObjectNode: Oral Paliperidone Extended-Release"}, {"color": "#97c2fc", "id": "NCT04172233", "label": "NCT04172233", "shape": "dot", "title": "SubjectNode: NCT04172233"}, {"color": "#97c2fc", "id": "mPASI-90", "label": "mPASI-90", "shape": "dot", "title": "ObjectNode: mPASI-90"}, {"color": "#97c2fc", "id": "PASI \u2265 12 points", "label": "PASI \u2265 12 points", "shape": "dot", "title": "ObjectNode: PASI \u2265 12 points"}, {"color": "#97c2fc", "id": "AKST1210", "label": "AKST1210", "shape": "dot", "title": "ObjectNode: AKST1210"}, {"color": "#97c2fc", "id": "Change in Physician\u0027s Global Assessment", "label": "Change in Physician\u0027s Global Assessment", "shape": "dot", "title": "ObjectNode: Change in Physician\u0027s Global Assessment"}, {"color": "#97c2fc", "id": "mPASI-75", "label": "mPASI-75", "shape": "dot", "title": "ObjectNode: mPASI-75"}, {"color": "#97c2fc", "id": "10% body surface areas", "label": "10% body surface areas", "shape": "dot", "title": "ObjectNode: 10% body surface areas"}, {"color": "#97c2fc", "id": "Physician\u0027s global assessment scores", "label": "Physician\u0027s global assessment scores", "shape": "dot", "title": "ObjectNode: Physician\u0027s global assessment scores"}, {"color": "#97c2fc", "id": "NCT05522387", "label": "NCT05522387", "shape": "dot", "title": "SubjectNode: NCT05522387"}, {"color": "#97c2fc", "id": "XPro1595", "label": "XPro1595", "shape": "dot", "title": "ObjectNode: XPro1595"}, {"color": "#97c2fc", "id": "Clinical Dementia Rating-Sum of Boxes", "label": "Clinical Dementia Rating-Sum of Boxes", "shape": "dot", "title": "ObjectNode: Clinical Dementia Rating-Sum of Boxes"}, {"color": "#97c2fc", "id": "predefined criteria", "label": "predefined criteria", "shape": "dot", "title": "ObjectNode: predefined criteria"}, {"color": "#97c2fc", "id": "NCT00848354", "label": "NCT00848354", "shape": "dot", "title": "SubjectNode: NCT00848354"}, {"color": "#97c2fc", "id": "ACR20 Responders", "label": "ACR20 Responders", "shape": "dot", "title": "ObjectNode: ACR20 Responders"}, {"color": "#97c2fc", "id": "HAI Score", "label": "HAI Score", "shape": "dot", "title": "ObjectNode: HAI Score"}, {"color": "#97c2fc", "id": "Etokimab", "label": "Etokimab", "shape": "dot", "title": "ObjectNode: Etokimab"}, {"color": "#97c2fc", "id": "SF36 Score", "label": "SF36 Score", "shape": "dot", "title": "ObjectNode: SF36 Score"}, {"color": "#97c2fc", "id": "arthritis pain", "label": "arthritis pain", "shape": "dot", "title": "ObjectNode: arthritis pain"}, {"color": "#97c2fc", "id": "NCT02674633", "label": "NCT02674633", "shape": "dot", "title": "SubjectNode: NCT02674633"}, {"color": "#97c2fc", "id": "ADHD-RS-IV Scores", "label": "ADHD-RS-IV Scores", "shape": "dot", "title": "ObjectNode: ADHD-RS-IV Scores"}, {"color": "#97c2fc", "id": "TOVA API", "label": "TOVA API", "shape": "dot", "title": "ObjectNode: TOVA API"}, {"color": "#97c2fc", "id": "Software", "label": "Software", "shape": "dot", "title": "ObjectNode: Software"}, {"color": "#97c2fc", "id": "DSM-5 diagnostic criteria", "label": "DSM-5 diagnostic criteria", "shape": "dot", "title": "ObjectNode: DSM-5 diagnostic criteria"}, {"color": "#97c2fc", "id": "ADHD-RS change", "label": "ADHD-RS change", "shape": "dot", "title": "ObjectNode: ADHD-RS change"}, {"color": "#97c2fc", "id": "NCT00886587", "label": "NCT00886587", "shape": "dot", "title": "SubjectNode: NCT00886587"}, {"color": "#97c2fc", "id": "device intervention", "label": "device intervention", "shape": "dot", "title": "ObjectNode: device intervention"}, {"color": "#97c2fc", "id": "EASI score at Week 48", "label": "EASI score at Week 48", "shape": "dot", "title": "ObjectNode: EASI score at Week 48"}, {"color": "#97c2fc", "id": "Able to provide informed consent", "label": "Able to provide informed consent", "shape": "dot", "title": "ObjectNode: Able to provide informed consent"}, {"color": "#97c2fc", "id": "Diagnosis of AD/ADRD", "label": "Diagnosis of AD/ADRD", "shape": "dot", "title": "ObjectNode: Diagnosis of AD/ADRD"}, {"color": "#97c2fc", "id": "Itch Score Day 43", "label": "Itch Score Day 43", "shape": "dot", "title": "ObjectNode: Itch Score Day 43"}, {"color": "#97c2fc", "id": "IGADA Score Day 43", "label": "IGADA Score Day 43", "shape": "dot", "title": "ObjectNode: IGADA Score Day 43"}, {"color": "#97c2fc", "id": "Post-menarchal female", "label": "Post-menarchal female", "shape": "dot", "title": "ObjectNode: Post-menarchal female"}, {"color": "#97c2fc", "id": "negative urine pregnancy test result", "label": "negative urine pregnancy test result", "shape": "dot", "title": "ObjectNode: negative urine pregnancy test result"}, {"color": "#97c2fc", "id": "NCT05054387", "label": "NCT05054387", "shape": "dot", "title": "SubjectNode: NCT05054387"}, {"color": "#97c2fc", "id": "eGFR \u003e 60 ml/min/1.73 m2", "label": "eGFR \u003e 60 ml/min/1.73 m2", "shape": "dot", "title": "ObjectNode: eGFR \u003e 60 ml/min/1.73 m2"}, {"color": "#97c2fc", "id": "12 years or older", "label": "12 years or older", "shape": "dot", "title": "ObjectNode: 12 years or older"}, {"color": "#97c2fc", "id": "plasma or leukocyte \u03b1GAL activity deficient", "label": "plasma or leukocyte \u03b1GAL activity deficient", "shape": "dot", "title": "ObjectNode: plasma or leukocyte \u03b1GAL activity deficient"}, {"color": "#97c2fc", "id": "Fabrazyme", "label": "Fabrazyme", "shape": "dot", "title": "ObjectNode: Fabrazyme"}, {"color": "#97c2fc", "id": "diagnosed with Fabry disease", "label": "diagnosed with Fabry disease", "shape": "dot", "title": "ObjectNode: diagnosed with Fabry disease"}, {"color": "#97c2fc", "id": "change of Fabry disease symptoms", "label": "change of Fabry disease symptoms", "shape": "dot", "title": "ObjectNode: change of Fabry disease symptoms"}, {"color": "#97c2fc", "id": "naive to agalsidase beta", "label": "naive to agalsidase beta", "shape": "dot", "title": "ObjectNode: naive to agalsidase beta"}, {"color": "#97c2fc", "id": "NCT04360187", "label": "NCT04360187", "shape": "dot", "title": "SubjectNode: NCT04360187"}, {"color": "#97c2fc", "id": "Serious AEs", "label": "Serious AEs", "shape": "dot", "title": "ObjectNode: Serious AEs"}, {"color": "#97c2fc", "id": "ages 2 years and older", "label": "ages 2 years and older", "shape": "dot", "title": "ObjectNode: ages 2 years and older"}, {"color": "#97c2fc", "id": "Eczema Area and Severity Index (EASI) of \u226512 and \\\u003c48", "label": "Eczema Area and Severity Index (EASI) of \u226512 and \\\u003c48", "shape": "dot", "title": "ObjectNode: Eczema Area and Severity Index (EASI) of \u226512 and \\\u003c48"}, {"color": "#97c2fc", "id": "Crisaborole", "label": "Crisaborole", "shape": "dot", "title": "ObjectNode: Crisaborole"}, {"color": "#97c2fc", "id": "NCT00678587", "label": "NCT00678587", "shape": "dot", "title": "SubjectNode: NCT00678587"}, {"color": "#97c2fc", "id": "Thrombocytopenia", "label": "Thrombocytopenia", "shape": "dot", "title": "ObjectNode: Thrombocytopenia"}, {"color": "#97c2fc", "id": "Hepatobiliary fibrosis", "label": "Hepatobiliary fibrosis", "shape": "dot", "title": "ObjectNode: Hepatobiliary fibrosis"}, {"color": "#97c2fc", "id": "platelet count \u2265 100", "label": "platelet count \u2265 100", "shape": "dot", "title": "ObjectNode: platelet count \u2265 100"}, {"color": "#97c2fc", "id": "Change in bleeding score", "label": "Change in bleeding score", "shape": "dot", "title": "ObjectNode: Change in bleeding score"}, {"color": "#97c2fc", "id": "Platelet transfusion independence", "label": "Platelet transfusion independence", "shape": "dot", "title": "ObjectNode: Platelet transfusion independence"}, {"color": "#97c2fc", "id": "Switched to eltrombopag or romiplostim", "label": "Switched to eltrombopag or romiplostim", "shape": "dot", "title": "ObjectNode: Switched to eltrombopag or romiplostim"}, {"color": "#97c2fc", "id": "NCT01098487", "label": "NCT01098487", "shape": "dot", "title": "SubjectNode: NCT01098487"}, {"color": "#97c2fc", "id": "Collagen Level", "label": "Collagen Level", "shape": "dot", "title": "ObjectNode: Collagen Level"}, {"color": "#97c2fc", "id": "Chronic Immune Thrombocytopenic Purpura", "label": "Chronic Immune Thrombocytopenic Purpura", "shape": "dot", "title": "ObjectNode: Chronic Immune Thrombocytopenic Purpura"}, {"color": "#97c2fc", "id": "MF Grade change", "label": "MF Grade change", "shape": "dot", "title": "ObjectNode: MF Grade change"}, {"color": "#97c2fc", "id": "centrally-reviewed BM biopsy", "label": "centrally-reviewed BM biopsy", "shape": "dot", "title": "ObjectNode: centrally-reviewed BM biopsy"}, {"color": "#97c2fc", "id": "NCT03772587", "label": "NCT03772587", "shape": "dot", "title": "SubjectNode: NCT03772587"}, {"color": "#97c2fc", "id": "Day 1 up to 393", "label": "Day 1 up to 393", "shape": "dot", "title": "ObjectNode: Day 1 up to 393"}, {"color": "#97c2fc", "id": "Number of Participants Reporting TEAEs", "label": "Number of Participants Reporting TEAEs", "shape": "dot", "title": "ObjectNode: Number of Participants Reporting TEAEs"}, {"color": "#97c2fc", "id": "Lambert Eaton Myasthenic Syndrome", "label": "Lambert Eaton Myasthenic Syndrome", "shape": "dot", "title": "ObjectNode: Lambert Eaton Myasthenic Syndrome"}, {"color": "#97c2fc", "id": "Number of SAEs", "label": "Number of SAEs", "shape": "dot", "title": "ObjectNode: Number of SAEs"}, {"color": "#97c2fc", "id": "M2951", "label": "M2951", "shape": "dot", "title": "ObjectNode: M2951"}, {"color": "#97c2fc", "id": "Number of participants with AESI", "label": "Number of participants with AESI", "shape": "dot", "title": "ObjectNode: Number of participants with AESI"}, {"color": "#97c2fc", "id": "NCT00876187", "label": "NCT00876187", "shape": "dot", "title": "SubjectNode: NCT00876187"}, {"color": "#97c2fc", "id": "Daily LBPI Score", "label": "Daily LBPI Score", "shape": "dot", "title": "ObjectNode: Daily LBPI Score"}, {"color": "#97c2fc", "id": "Chronic Low-Back Pain", "label": "Chronic Low-Back Pain", "shape": "dot", "title": "ObjectNode: Chronic Low-Back Pain"}, {"color": "#97c2fc", "id": "Baseline Observation Carried Forward", "label": "Baseline Observation Carried Forward", "shape": "dot", "title": "ObjectNode: Baseline Observation Carried Forward"}, {"color": "#97c2fc", "id": "Patient Global Improvement", "label": "Patient Global Improvement", "shape": "dot", "title": "ObjectNode: Patient Global Improvement"}, {"color": "#97c2fc", "id": "Subcutaneous Tanezumab", "label": "Subcutaneous Tanezumab", "shape": "dot", "title": "ObjectNode: Subcutaneous Tanezumab"}, {"color": "#97c2fc", "id": "QMG Total Score", "label": "QMG Total Score", "shape": "dot", "title": "ObjectNode: QMG Total Score"}, {"color": "#97c2fc", "id": "NCT00660387", "label": "NCT00660387", "shape": "dot", "title": "SubjectNode: NCT00660387"}, {"color": "#97c2fc", "id": "Levodopa/Carbidopa/Entacapone", "label": "Levodopa/Carbidopa/Entacapone", "shape": "dot", "title": "ObjectNode: Levodopa/Carbidopa/Entacapone"}, {"color": "#97c2fc", "id": "Average Daily Normalized \"Off\" Time", "label": "Average Daily Normalized \"Off\" Time", "shape": "dot", "title": "ObjectNode: Average Daily Normalized \"Off\" Time"}, {"color": "#97c2fc", "id": "Average Daily Normalized \"On\" Time", "label": "Average Daily Normalized \"On\" Time", "shape": "dot", "title": "ObjectNode: Average Daily Normalized \"On\" Time"}, {"color": "#97c2fc", "id": "Change From Baseline in Parkinson\u0027s Disease Questionnaire-39 Summary Index Score", "label": "Change From Baseline in Parkinson\u0027s Disease Questionnaire-39 Summary Index Score", "shape": "dot", "title": "ObjectNode: Change From Baseline in Parkinson\u0027s Disease Questionnaire-39 Summary Index Score"}, {"color": "#97c2fc", "id": "early-stage Parkinson\u0027s disease", "label": "early-stage Parkinson\u0027s disease", "shape": "dot", "title": "ObjectNode: early-stage Parkinson\u0027s disease"}, {"color": "#97c2fc", "id": "NCT01255787", "label": "NCT01255787", "shape": "dot", "title": "SubjectNode: NCT01255787"}, {"color": "#97c2fc", "id": "Major Depressive Disorder With Mixed Features", "label": "Major Depressive Disorder With Mixed Features", "shape": "dot", "title": "ObjectNode: Major Depressive Disorder With Mixed Features"}, {"color": "#97c2fc", "id": "Suvorexant", "label": "Suvorexant", "shape": "dot", "title": "ObjectNode: Suvorexant"}, {"color": "#97c2fc", "id": "Baseline value", "label": "Baseline value", "shape": "dot", "title": "ObjectNode: Baseline value"}, {"color": "#97c2fc", "id": "CGI-C Scale Scores", "label": "CGI-C Scale Scores", "shape": "dot", "title": "ObjectNode: CGI-C Scale Scores"}, {"color": "#97c2fc", "id": "MADRS Response Rate", "label": "MADRS Response Rate", "shape": "dot", "title": "ObjectNode: MADRS Response Rate"}, {"color": "#97c2fc", "id": "MADRS total score \u226522", "label": "MADRS total score \u226522", "shape": "dot", "title": "ObjectNode: MADRS total score \u226522"}, {"color": "#97c2fc", "id": "MADRS Remission at Week 8", "label": "MADRS Remission at Week 8", "shape": "dot", "title": "ObjectNode: MADRS Remission at Week 8"}, {"color": "#97c2fc", "id": "NCT00877487", "label": "NCT00877487", "shape": "dot", "title": "SubjectNode: NCT00877487"}, {"color": "#97c2fc", "id": "Concerta", "label": "Concerta", "shape": "dot", "title": "ObjectNode: Concerta"}, {"color": "#97c2fc", "id": "documented ADHD diagnosis", "label": "documented ADHD diagnosis", "shape": "dot", "title": "ObjectNode: documented ADHD diagnosis"}, {"color": "#97c2fc", "id": "Documented history of ADHD diagnosis", "label": "Documented history of ADHD diagnosis", "shape": "dot", "title": "ObjectNode: Documented history of ADHD diagnosis"}, {"color": "#97c2fc", "id": "stable SPD489 treatment 6 months", "label": "stable SPD489 treatment 6 months", "shape": "dot", "title": "ObjectNode: stable SPD489 treatment 6 months"}, {"color": "#97c2fc", "id": "NCT01524887", "label": "NCT01524887", "shape": "dot", "title": "SubjectNode: NCT01524887"}, {"color": "#97c2fc", "id": "Change in ADCS-ADL", "label": "Change in ADCS-ADL", "shape": "dot", "title": "ObjectNode: Change in ADCS-ADL"}, {"color": "#97c2fc", "id": "Baseline to \u226420 weeks", "label": "Baseline to \u226420 weeks", "shape": "dot", "title": "ObjectNode: Baseline to \u226420 weeks"}, {"color": "#97c2fc", "id": "ADAS-Cog-11 Scores", "label": "ADAS-Cog-11 Scores", "shape": "dot", "title": "ObjectNode: ADAS-Cog-11 Scores"}, {"color": "#97c2fc", "id": "IGIV", "label": "IGIV", "shape": "dot", "title": "ObjectNode: IGIV"}, {"color": "#97c2fc", "id": "Neuropsychiatry Inventory", "label": "Neuropsychiatry Inventory", "shape": "dot", "title": "ObjectNode: Neuropsychiatry Inventory"}, {"color": "#97c2fc", "id": "NCT01617187", "label": "NCT01617187", "shape": "dot", "title": "SubjectNode: NCT01617187"}, {"color": "#97c2fc", "id": "Pimavanserin", "label": "Pimavanserin", "shape": "dot", "title": "ObjectNode: Pimavanserin"}, {"color": "#97c2fc", "id": "PANSS Responders", "label": "PANSS Responders", "shape": "dot", "title": "ObjectNode: PANSS Responders"}, {"color": "#97c2fc", "id": "NCT03465787", "label": "NCT03465787", "shape": "dot", "title": "SubjectNode: NCT03465787"}, {"color": "#97c2fc", "id": "no prior lurasidone trial", "label": "no prior lurasidone trial", "shape": "dot", "title": "ObjectNode: no prior lurasidone trial"}, {"color": "#97c2fc", "id": "switched from other antipsychotic drugs", "label": "switched from other antipsychotic drugs", "shape": "dot", "title": "ObjectNode: switched from other antipsychotic drugs"}, {"color": "#97c2fc", "id": "age 18 or above and below 65", "label": "age 18 or above and below 65", "shape": "dot", "title": "ObjectNode: age 18 or above and below 65"}, {"color": "#97c2fc", "id": "no drug abuse", "label": "no drug abuse", "shape": "dot", "title": "ObjectNode: no drug abuse"}, {"color": "#97c2fc", "id": "no chronic CNS disease", "label": "no chronic CNS disease", "shape": "dot", "title": "ObjectNode: no chronic CNS disease"}, {"color": "#97c2fc", "id": "no pregnancy or breastfeeding", "label": "no pregnancy or breastfeeding", "shape": "dot", "title": "ObjectNode: no pregnancy or breastfeeding"}, {"color": "#97c2fc", "id": "reasonably good health", "label": "reasonably good health", "shape": "dot", "title": "ObjectNode: reasonably good health"}, {"color": "#97c2fc", "id": "able to cooperate", "label": "able to cooperate", "shape": "dot", "title": "ObjectNode: able to cooperate"}, {"color": "#97c2fc", "id": "NCT05865496", "label": "NCT05865496", "shape": "dot", "title": "SubjectNode: NCT05865496"}, {"color": "#97c2fc", "id": "UPSIT Score", "label": "UPSIT Score", "shape": "dot", "title": "ObjectNode: UPSIT Score"}, {"color": "#97c2fc", "id": "611", "label": "611", "shape": "dot", "title": "ObjectNode: 611"}, {"color": "#97c2fc", "id": "Nasal blockade/obstruction/congestion", "label": "Nasal blockade/obstruction/congestion", "shape": "dot", "title": "ObjectNode: Nasal blockade/obstruction/congestion"}, {"color": "#97c2fc", "id": "Lysholm Score", "label": "Lysholm Score", "shape": "dot", "title": "ObjectNode: Lysholm Score"}, {"color": "#97c2fc", "id": "Nasal polyp score \u2265 4", "label": "Nasal polyp score \u2265 4", "shape": "dot", "title": "ObjectNode: Nasal polyp score \u2265 4"}, {"color": "#97c2fc", "id": "Up to 48 weeks", "label": "Up to 48 weeks", "shape": "dot", "title": "ObjectNode: Up to 48 weeks"}, {"color": "#97c2fc", "id": "Bilateral NPS", "label": "Bilateral NPS", "shape": "dot", "title": "ObjectNode: Bilateral NPS"}, {"color": "#97c2fc", "id": "NCT03909516", "label": "NCT03909516", "shape": "dot", "title": "SubjectNode: NCT03909516"}, {"color": "#97c2fc", "id": "Average Evening Pain Intensity", "label": "Average Evening Pain Intensity", "shape": "dot", "title": "ObjectNode: Average Evening Pain Intensity"}, {"color": "#97c2fc", "id": "Iovera\u00b0 Device", "label": "Iovera\u00b0 Device", "shape": "dot", "title": "ObjectNode: Iovera\u00b0 Device"}, {"color": "#97c2fc", "id": "Single Assessment Numerical Evaluation", "label": "Single Assessment Numerical Evaluation", "shape": "dot", "title": "ObjectNode: Single Assessment Numerical Evaluation"}, {"color": "#97c2fc", "id": "Lateral Ankle Ligament Reconstruction", "label": "Lateral Ankle Ligament Reconstruction", "shape": "dot", "title": "ObjectNode: Lateral Ankle Ligament Reconstruction"}, {"color": "#97c2fc", "id": "Area-Under-Effect", "label": "Area-Under-Effect", "shape": "dot", "title": "ObjectNode: Area-Under-Effect"}, {"color": "#97c2fc", "id": "Baseline to 10 days post-surgery", "label": "Baseline to 10 days post-surgery", "shape": "dot", "title": "ObjectNode: Baseline to 10 days post-surgery"}, {"color": "#97c2fc", "id": "Oxford Knee Score", "label": "Oxford Knee Score", "shape": "dot", "title": "ObjectNode: Oxford Knee Score"}, {"color": "#97c2fc", "id": "NCT03836716", "label": "NCT03836716", "shape": "dot", "title": "SubjectNode: NCT03836716"}, {"color": "#97c2fc", "id": "Hematology Screening parameters", "label": "Hematology Screening parameters", "shape": "dot", "title": "ObjectNode: Hematology Screening parameters"}, {"color": "#97c2fc", "id": "Aramchol Meglumine", "label": "Aramchol Meglumine", "shape": "dot", "title": "ObjectNode: Aramchol Meglumine"}, {"color": "#97c2fc", "id": "Mean Change EASI", "label": "Mean Change EASI", "shape": "dot", "title": "ObjectNode: Mean Change EASI"}, {"color": "#97c2fc", "id": "IMP dose", "label": "IMP dose", "shape": "dot", "title": "ObjectNode: IMP dose"}, {"color": "#97c2fc", "id": "NCT02111096", "label": "NCT02111096", "shape": "dot", "title": "SubjectNode: NCT02111096"}, {"color": "#97c2fc", "id": "Fasting and Post meal Glucose", "label": "Fasting and Post meal Glucose", "shape": "dot", "title": "ObjectNode: Fasting and Post meal Glucose"}, {"color": "#97c2fc", "id": "ALT and AST elevation", "label": "ALT and AST elevation", "shape": "dot", "title": "ObjectNode: ALT and AST elevation"}, {"color": "#97c2fc", "id": "hepatic fat fraction \u2265 5%", "label": "hepatic fat fraction \u2265 5%", "shape": "dot", "title": "ObjectNode: hepatic fat fraction \u2265 5%"}, {"color": "#97c2fc", "id": "Fasting Triglyceride Levels", "label": "Fasting Triglyceride Levels", "shape": "dot", "title": "ObjectNode: Fasting Triglyceride Levels"}, {"color": "#97c2fc", "id": "Baseline Weight", "label": "Baseline Weight", "shape": "dot", "title": "ObjectNode: Baseline Weight"}, {"color": "#97c2fc", "id": "Hemoglobin A1c Levels", "label": "Hemoglobin A1c Levels", "shape": "dot", "title": "ObjectNode: Hemoglobin A1c Levels"}, {"color": "#97c2fc", "id": "NCT02046616", "label": "NCT02046616", "shape": "dot", "title": "SubjectNode: NCT02046616"}, {"color": "#97c2fc", "id": "Change from Baseline in DAS28-CRP", "label": "Change from Baseline in DAS28-CRP", "shape": "dot", "title": "ObjectNode: Change from Baseline in DAS28-CRP"}, {"color": "#97c2fc", "id": "methotrexate-inadequate responders", "label": "methotrexate-inadequate responders", "shape": "dot", "title": "ObjectNode: methotrexate-inadequate responders"}, {"color": "#97c2fc", "id": "Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 30% Response", "label": "Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 30% Response", "shape": "dot", "title": "ObjectNode: Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 30% Response"}, {"color": "#97c2fc", "id": "Tocilizumab Subcutaneous", "label": "Tocilizumab Subcutaneous", "shape": "dot", "title": "ObjectNode: Tocilizumab Subcutaneous"}, {"color": "#97c2fc", "id": "NCT01647516", "label": "NCT01647516", "shape": "dot", "title": "SubjectNode: NCT01647516"}, {"color": "#97c2fc", "id": "Clinical Response 100", "label": "Clinical Response 100", "shape": "dot", "title": "ObjectNode: Clinical Response 100"}, {"color": "#97c2fc", "id": "Ozarelix", "label": "Ozarelix", "shape": "dot", "title": "ObjectNode: Ozarelix"}, {"color": "#97c2fc", "id": "NCT01058096", "label": "NCT01058096", "shape": "dot", "title": "SubjectNode: NCT01058096"}, {"color": "#97c2fc", "id": "Aripiprazole Lauroxil", "label": "Aripiprazole Lauroxil", "shape": "dot", "title": "ObjectNode: Aripiprazole Lauroxil"}, {"color": "#97c2fc", "id": "Adults With Bipolar I Disorder", "label": "Adults With Bipolar I Disorder", "shape": "dot", "title": "ObjectNode: Adults With Bipolar I Disorder"}, {"color": "#97c2fc", "id": "YMRS score", "label": "YMRS score", "shape": "dot", "title": "ObjectNode: YMRS score"}, {"color": "#97c2fc", "id": "CGI-Improvement Score", "label": "CGI-Improvement Score", "shape": "dot", "title": "ObjectNode: CGI-Improvement Score"}, {"color": "#97c2fc", "id": "NCT02317016", "label": "NCT02317016", "shape": "dot", "title": "SubjectNode: NCT02317016"}, {"color": "#97c2fc", "id": "AUC of Rosuvastatin", "label": "AUC of Rosuvastatin", "shape": "dot", "title": "ObjectNode: AUC of Rosuvastatin"}, {"color": "#97c2fc", "id": "AZD9668", "label": "AZD9668", "shape": "dot", "title": "ObjectNode: AZD9668"}, {"color": "#97c2fc", "id": "tmax of rosuvastatin", "label": "tmax of rosuvastatin", "shape": "dot", "title": "ObjectNode: tmax of rosuvastatin"}, {"color": "#97c2fc", "id": "Maximally Tolerated Statin", "label": "Maximally Tolerated Statin", "shape": "dot", "title": "ObjectNode: Maximally Tolerated Statin"}, {"color": "#97c2fc", "id": "Metastatic Non-squamous Non-Small-Cell Lung Cancer", "label": "Metastatic Non-squamous Non-Small-Cell Lung Cancer", "shape": "dot", "title": "ObjectNode: Metastatic Non-squamous Non-Small-Cell Lung Cancer"}, {"color": "#97c2fc", "id": "NCT04839016", "label": "NCT04839016", "shape": "dot", "title": "SubjectNode: NCT04839016"}, {"color": "#97c2fc", "id": "inadequately controlled by topical treatment", "label": "inadequately controlled by topical treatment", "shape": "dot", "title": "ObjectNode: inadequately controlled by topical treatment"}, {"color": "#97c2fc", "id": "PASI-75 Score", "label": "PASI-75 Score", "shape": "dot", "title": "ObjectNode: PASI-75 Score"}, {"color": "#97c2fc", "id": "sPGA of Clear or Almost Clear at Week 16", "label": "sPGA of Clear or Almost Clear at Week 16", "shape": "dot", "title": "ObjectNode: sPGA of Clear or Almost Clear at Week 16"}, {"color": "#97c2fc", "id": "disease inadequately controlled", "label": "disease inadequately controlled", "shape": "dot", "title": "ObjectNode: disease inadequately controlled"}, {"color": "#97c2fc", "id": "inadequate topical response", "label": "inadequate topical response", "shape": "dot", "title": "ObjectNode: inadequate topical response"}, {"color": "#97c2fc", "id": "BSA score \u2265 10%", "label": "BSA score \u2265 10%", "shape": "dot", "title": "ObjectNode: BSA score \u2265 10%"}, {"color": "#97c2fc", "id": "PASI-75 at Week 24", "label": "PASI-75 at Week 24", "shape": "dot", "title": "ObjectNode: PASI-75 at Week 24"}, {"color": "#97c2fc", "id": "Mild to Severe Plaque Psoriasis", "label": "Mild to Severe Plaque Psoriasis", "shape": "dot", "title": "ObjectNode: Mild to Severe Plaque Psoriasis"}, {"color": "#97c2fc", "id": "sPGA score \u2265 3 points", "label": "sPGA score \u2265 3 points", "shape": "dot", "title": "ObjectNode: sPGA score \u2265 3 points"}, {"color": "#97c2fc", "id": "SHR0302", "label": "SHR0302", "shape": "dot", "title": "ObjectNode: SHR0302"}, {"color": "#97c2fc", "id": "NCT03971422", "label": "NCT03971422", "shape": "dot", "title": "SubjectNode: NCT03971422"}, {"color": "#97c2fc", "id": "Baseline up to Day 21", "label": "Baseline up to Day 21", "shape": "dot", "title": "ObjectNode: Baseline up to Day 21"}, {"color": "#97c2fc", "id": "Romosozumab", "label": "Romosozumab", "shape": "dot", "title": "ObjectNode: Romosozumab"}, {"color": "#97c2fc", "id": "Percentage of Participants Achieving MG-ADL Response", "label": "Percentage of Participants Achieving MG-ADL Response", "shape": "dot", "title": "ObjectNode: Percentage of Participants Achieving MG-ADL Response"}, {"color": "#97c2fc", "id": "NCT03845075", "label": "NCT03845075", "shape": "dot", "title": "SubjectNode: NCT03845075"}, {"color": "#97c2fc", "id": "Liver function parameters", "label": "Liver function parameters", "shape": "dot", "title": "ObjectNode: Liver function parameters"}, {"color": "#97c2fc", "id": "Metoprolol Succinate Prolonged-Release Tablet", "label": "Metoprolol Succinate Prolonged-Release Tablet", "shape": "dot", "title": "ObjectNode: Metoprolol Succinate Prolonged-Release Tablet"}, {"color": "#97c2fc", "id": "Number of Participants With Any Treatment-Emergent Adverse Events", "label": "Number of Participants With Any Treatment-Emergent Adverse Events", "shape": "dot", "title": "ObjectNode: Number of Participants With Any Treatment-Emergent Adverse Events"}, {"color": "#97c2fc", "id": "Acquired Hypothalamic Obesity", "label": "Acquired Hypothalamic Obesity", "shape": "dot", "title": "ObjectNode: Acquired Hypothalamic Obesity"}, {"color": "#97c2fc", "id": "Change from Baseline in Average Heart Rate", "label": "Change from Baseline in Average Heart Rate", "shape": "dot", "title": "ObjectNode: Change from Baseline in Average Heart Rate"}, {"color": "#97c2fc", "id": "Tesofensine", "label": "Tesofensine", "shape": "dot", "title": "ObjectNode: Tesofensine"}, {"color": "#97c2fc", "id": "Serum Creatinine Elevations", "label": "Serum Creatinine Elevations", "shape": "dot", "title": "ObjectNode: Serum Creatinine Elevations"}, {"color": "#97c2fc", "id": "Hematology Laboratory Results", "label": "Hematology Laboratory Results", "shape": "dot", "title": "ObjectNode: Hematology Laboratory Results"}, {"color": "#97c2fc", "id": "NCT04507659", "label": "NCT04507659", "shape": "dot", "title": "SubjectNode: NCT04507659"}, {"color": "#97c2fc", "id": "Sacroiliitis", "label": "Sacroiliitis", "shape": "dot", "title": "ObjectNode: Sacroiliitis"}, {"color": "#97c2fc", "id": "\u2265 20%", "label": "\u2265 20%", "shape": "dot", "title": "ObjectNode: \u2265 20%"}, {"color": "#97c2fc", "id": "ASAS20 response at Week 12", "label": "ASAS20 response at Week 12", "shape": "dot", "title": "ObjectNode: ASAS20 response at Week 12"}, {"color": "#97c2fc", "id": "Jaktinib Hydrochloride Tablets", "label": "Jaktinib Hydrochloride Tablets", "shape": "dot", "title": "ObjectNode: Jaktinib Hydrochloride Tablets"}, {"color": "#97c2fc", "id": "NCT02868359", "label": "NCT02868359", "shape": "dot", "title": "SubjectNode: NCT02868359"}, {"color": "#97c2fc", "id": "Pain scoring", "label": "Pain scoring", "shape": "dot", "title": "ObjectNode: Pain scoring"}, {"color": "#97c2fc", "id": "Pain Interference on Sleep", "label": "Pain Interference on Sleep", "shape": "dot", "title": "ObjectNode: Pain Interference on Sleep"}, {"color": "#97c2fc", "id": "Neck Disability Index Score", "label": "Neck Disability Index Score", "shape": "dot", "title": "ObjectNode: Neck Disability Index Score"}, {"color": "#97c2fc", "id": "Lyrica", "label": "Lyrica", "shape": "dot", "title": "ObjectNode: Lyrica"}, {"color": "#97c2fc", "id": "EuroQol 5 Dimensions 5 Levels", "label": "EuroQol 5 Dimensions 5 Levels", "shape": "dot", "title": "ObjectNode: EuroQol 5 Dimensions 5 Levels"}, {"color": "#97c2fc", "id": "Rescue medication consumption", "label": "Rescue medication consumption", "shape": "dot", "title": "ObjectNode: Rescue medication consumption"}, {"color": "#97c2fc", "id": "NCT01649375", "label": "NCT01649375", "shape": "dot", "title": "SubjectNode: NCT01649375"}, {"color": "#97c2fc", "id": "securkinumab", "label": "securkinumab", "shape": "dot", "title": "ObjectNode: securkinumab"}, {"color": "#97c2fc", "id": "high-sensitivity CRP", "label": "high-sensitivity CRP", "shape": "dot", "title": "ObjectNode: high-sensitivity CRP"}, {"color": "#97c2fc", "id": "NCT00809159", "label": "NCT00809159", "shape": "dot", "title": "SubjectNode: NCT00809159"}, {"color": "#97c2fc", "id": "AIN457", "label": "AIN457", "shape": "dot", "title": "ObjectNode: AIN457"}, {"color": "#97c2fc", "id": "Moderate to severe CD", "label": "Moderate to severe CD", "shape": "dot", "title": "ObjectNode: Moderate to severe CD"}, {"color": "#97c2fc", "id": "BASMI Score", "label": "BASMI Score", "shape": "dot", "title": "ObjectNode: BASMI Score"}, {"color": "#97c2fc", "id": "NCT00365859", "label": "NCT00365859", "shape": "dot", "title": "SubjectNode: NCT00365859"}, {"color": "#97c2fc", "id": "screening to week 52/early termination", "label": "screening to week 52/early termination", "shape": "dot", "title": "ObjectNode: screening to week 52/early termination"}, {"color": "#97c2fc", "id": "Autism Spectrum Disorders", "label": "Autism Spectrum Disorders", "shape": "dot", "title": "ObjectNode: Autism Spectrum Disorders"}, {"color": "#97c2fc", "id": "Abnormal Involuntary Movement Scale", "label": "Abnormal Involuntary Movement Scale", "shape": "dot", "title": "ObjectNode: Abnormal Involuntary Movement Scale"}, {"color": "#97c2fc", "id": "NCT04312659", "label": "NCT04312659", "shape": "dot", "title": "SubjectNode: NCT04312659"}, {"color": "#97c2fc", "id": "Children aged 2-15 years", "label": "Children aged 2-15 years", "shape": "dot", "title": "ObjectNode: Children aged 2-15 years"}, {"color": "#97c2fc", "id": "TA-650(Infliximab)", "label": "TA-650(Infliximab)", "shape": "dot", "title": "ObjectNode: TA-650(Infliximab)"}, {"color": "#97c2fc", "id": "Change From Baseline in Height-for-age Z-score", "label": "Change From Baseline in Height-for-age Z-score", "shape": "dot", "title": "ObjectNode: Change From Baseline in Height-for-age Z-score"}, {"color": "#97c2fc", "id": "NCT04098575", "label": "NCT04098575", "shape": "dot", "title": "SubjectNode: NCT04098575"}, {"color": "#97c2fc", "id": "Biphasic Remogliflozin Etabonate", "label": "Biphasic Remogliflozin Etabonate", "shape": "dot", "title": "ObjectNode: Biphasic Remogliflozin Etabonate"}, {"color": "#97c2fc", "id": "NCT04731675", "label": "NCT04731675", "shape": "dot", "title": "SubjectNode: NCT04731675"}, {"color": "#97c2fc", "id": "AMX0035", "label": "AMX0035", "shape": "dot", "title": "ObjectNode: AMX0035"}, {"color": "#97c2fc", "id": "Tenosynovial Giant Cell Tumor of the Knee", "label": "Tenosynovial Giant Cell Tumor of the Knee", "shape": "dot", "title": "ObjectNode: Tenosynovial Giant Cell Tumor of the Knee"}, {"color": "#97c2fc", "id": "WOMAC physical function sub-score", "label": "WOMAC physical function sub-score", "shape": "dot", "title": "ObjectNode: WOMAC physical function sub-score"}, {"color": "#97c2fc", "id": "Overall Tumor Response", "label": "Overall Tumor Response", "shape": "dot", "title": "ObjectNode: Overall Tumor Response"}, {"color": "#97c2fc", "id": "Change in Active Range of Motion", "label": "Change in Active Range of Motion", "shape": "dot", "title": "ObjectNode: Change in Active Range of Motion"}, {"color": "#97c2fc", "id": "NCT03881059", "label": "NCT03881059", "shape": "dot", "title": "SubjectNode: NCT03881059"}, {"color": "#97c2fc", "id": "PASI100 response", "label": "PASI100 response", "shape": "dot", "title": "ObjectNode: PASI100 response"}, {"color": "#97c2fc", "id": "BMS-986231", "label": "BMS-986231", "shape": "dot", "title": "ObjectNode: BMS-986231"}, {"color": "#97c2fc", "id": "History psoriatic arthritis", "label": "History psoriatic arthritis", "shape": "dot", "title": "ObjectNode: History psoriatic arthritis"}, {"color": "#97c2fc", "id": "tender/painful joint count", "label": "tender/painful joint count", "shape": "dot", "title": "ObjectNode: tender/painful joint count"}, {"color": "#97c2fc", "id": "NCT04680975", "label": "NCT04680975", "shape": "dot", "title": "SubjectNode: NCT04680975"}, {"color": "#97c2fc", "id": "Oral Belumosudil", "label": "Oral Belumosudil", "shape": "dot", "title": "ObjectNode: Oral Belumosudil"}, {"color": "#97c2fc", "id": "new onset lung fibrosis", "label": "new onset lung fibrosis", "shape": "dot", "title": "ObjectNode: new onset lung fibrosis"}, {"color": "#97c2fc", "id": "Percent of the predicted forced expiratory volume over 1 second", "label": "Percent of the predicted forced expiratory volume over 1 second", "shape": "dot", "title": "ObjectNode: Percent of the predicted forced expiratory volume over 1 second"}, {"color": "#97c2fc", "id": "current active renal disease", "label": "current active renal disease", "shape": "dot", "title": "ObjectNode: current active renal disease"}, {"color": "#97c2fc", "id": "mRSS", "label": "mRSS", "shape": "dot", "title": "ObjectNode: mRSS"}, {"color": "#97c2fc", "id": "Diffuse Systemic Sclerosis", "label": "Diffuse Systemic Sclerosis", "shape": "dot", "title": "ObjectNode: Diffuse Systemic Sclerosis"}, {"color": "#97c2fc", "id": "cardiac failure", "label": "cardiac failure", "shape": "dot", "title": "ObjectNode: cardiac failure"}, {"color": "#97c2fc", "id": "Pulmonary Vascular Disease", "label": "Pulmonary Vascular Disease", "shape": "dot", "title": "ObjectNode: Pulmonary Vascular Disease"}, {"color": "#97c2fc", "id": "SHAQ-DI", "label": "SHAQ-DI", "shape": "dot", "title": "ObjectNode: SHAQ-DI"}, {"color": "#97c2fc", "id": "ACR CRISS composite score", "label": "ACR CRISS composite score", "shape": "dot", "title": "ObjectNode: ACR CRISS composite score"}, {"color": "#97c2fc", "id": "NCT01603459", "label": "NCT01603459", "shape": "dot", "title": "SubjectNode: NCT01603459"}, {"color": "#97c2fc", "id": "Onabotulinumtoxin A", "label": "Onabotulinumtoxin A", "shape": "dot", "title": "ObjectNode: Onabotulinumtoxin A"}, {"color": "#97c2fc", "id": "Ashworth Score", "label": "Ashworth Score", "shape": "dot", "title": "ObjectNode: Ashworth Score"}, {"color": "#97c2fc", "id": "Post-Stroke Upper Limb Spasticity", "label": "Post-Stroke Upper Limb Spasticity", "shape": "dot", "title": "ObjectNode: Post-Stroke Upper Limb Spasticity"}, {"color": "#97c2fc", "id": "Investigator\u0027s Global Assessment of Efficacy", "label": "Investigator\u0027s Global Assessment of Efficacy", "shape": "dot", "title": "ObjectNode: Investigator\u0027s Global Assessment of Efficacy"}, {"color": "#97c2fc", "id": "Injection Cycle", "label": "Injection Cycle", "shape": "dot", "title": "ObjectNode: Injection Cycle"}, {"color": "#97c2fc", "id": "NCT00614575", "label": "NCT00614575", "shape": "dot", "title": "SubjectNode: NCT00614575"}, {"color": "#97c2fc", "id": "Modified Barthel Index", "label": "Modified Barthel Index", "shape": "dot", "title": "ObjectNode: Modified Barthel Index"}, {"color": "#97c2fc", "id": "UPDRS Part I Item 3 Score", "label": "UPDRS Part I Item 3 Score", "shape": "dot", "title": "ObjectNode: UPDRS Part I Item 3 Score"}, {"color": "#97c2fc", "id": "depressed episode", "label": "depressed episode", "shape": "dot", "title": "ObjectNode: depressed episode"}, {"color": "#97c2fc", "id": "UPDRS Items 32 and 33 Composite Score", "label": "UPDRS Items 32 and 33 Composite Score", "shape": "dot", "title": "ObjectNode: UPDRS Items 32 and 33 Composite Score"}, {"color": "#97c2fc", "id": "Bech Melancholia Subscale Score", "label": "Bech Melancholia Subscale Score", "shape": "dot", "title": "ObjectNode: Bech Melancholia Subscale Score"}, {"color": "#97c2fc", "id": "Pramipexole Extended Release", "label": "Pramipexole Extended Release", "shape": "dot", "title": "ObjectNode: Pramipexole Extended Release"}, {"color": "#97c2fc", "id": "NCT02400775", "label": "NCT02400775", "shape": "dot", "title": "SubjectNode: NCT02400775"}, {"color": "#97c2fc", "id": "Office BP measurements", "label": "Office BP measurements", "shape": "dot", "title": "ObjectNode: Office BP measurements"}, {"color": "#97c2fc", "id": "High LDL-C", "label": "High LDL-C", "shape": "dot", "title": "ObjectNode: High LDL-C"}, {"color": "#97c2fc", "id": "Change in lipid-regulating protein levels", "label": "Change in lipid-regulating protein levels", "shape": "dot", "title": "ObjectNode: Change in lipid-regulating protein levels"}, {"color": "#97c2fc", "id": "Change in calcified component", "label": "Change in calcified component", "shape": "dot", "title": "ObjectNode: Change in calcified component"}, {"color": "#97c2fc", "id": "Change in number of microchannels", "label": "Change in number of microchannels", "shape": "dot", "title": "ObjectNode: Change in number of microchannels"}, {"color": "#97c2fc", "id": "Stage II essential hypertension", "label": "Stage II essential hypertension", "shape": "dot", "title": "ObjectNode: Stage II essential hypertension"}, {"color": "#97c2fc", "id": "Change in thickness of fibrous cap", "label": "Change in thickness of fibrous cap", "shape": "dot", "title": "ObjectNode: Change in thickness of fibrous cap"}, {"color": "#97c2fc", "id": "No recent unstable angina", "label": "No recent unstable angina", "shape": "dot", "title": "ObjectNode: No recent unstable angina"}, {"color": "#97c2fc", "id": "NCT02698475", "label": "NCT02698475", "shape": "dot", "title": "SubjectNode: NCT02698475"}, {"color": "#97c2fc", "id": "C-DLQI Score", "label": "C-DLQI Score", "shape": "dot", "title": "ObjectNode: C-DLQI Score"}, {"color": "#97c2fc", "id": "Failed standard treatment", "label": "Failed standard treatment", "shape": "dot", "title": "ObjectNode: Failed standard treatment"}, {"color": "#97c2fc", "id": "PGA score clear/almost clear", "label": "PGA score clear/almost clear", "shape": "dot", "title": "ObjectNode: PGA score clear/almost clear"}, {"color": "#97c2fc", "id": "NCT01351675", "label": "NCT01351675", "shape": "dot", "title": "SubjectNode: NCT01351675"}, {"color": "#97c2fc", "id": "Time-to-first event", "label": "Time-to-first event", "shape": "dot", "title": "ObjectNode: Time-to-first event"}, {"color": "#97c2fc", "id": "Bardoxolone Methyl", "label": "Bardoxolone Methyl", "shape": "dot", "title": "ObjectNode: Bardoxolone Methyl"}, {"color": "#97c2fc", "id": "Mean change in Systolic BP", "label": "Mean change in Systolic BP", "shape": "dot", "title": "ObjectNode: Mean change in Systolic BP"}, {"color": "#97c2fc", "id": "Time to First Relapse Event", "label": "Time to First Relapse Event", "shape": "dot", "title": "ObjectNode: Time to First Relapse Event"}, {"color": "#97c2fc", "id": "Treatment with an ACE inhibitor and/or an ARB", "label": "Treatment with an ACE inhibitor and/or an ARB", "shape": "dot", "title": "ObjectNode: Treatment with an ACE inhibitor and/or an ARB"}, {"color": "#97c2fc", "id": "Stable Dose Period", "label": "Stable Dose Period", "shape": "dot", "title": "ObjectNode: Stable Dose Period"}]);
                  edges = new vis.DataSet([{"arrows": "to", "from": "NCT03821493", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Advanced Solid Malignancies"}, {"arrows": "to", "from": "NCT03821493", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Hepatitis B e Antigen Seroconversion"}, {"arrows": "to", "from": "NCT03821493", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "hypersensitivity itraconazole"}, {"arrows": "to", "from": "NCT03821493", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "diagnosed chronic heart failure"}, {"arrows": "to", "from": "NCT03821493", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Body weight \u2265 45 kg"}, {"arrows": "to", "from": "NCT03821493", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "BMI 18 to 32 kg/m2"}, {"arrows": "to", "from": "NCT03821493", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Maximum Observed Plasma Analyte Concentration"}, {"arrows": "to", "from": "NCT03821493", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "AUCinf of PF-06835919"}, {"arrows": "to", "from": "NCT03821493", "label": "EVALUATES", "title": "EVALUATES", "to": "Isavuconazole"}, {"arrows": "to", "from": "NCT03821493", "label": "INVOLVES", "title": "INVOLVES", "to": "Healthy Fed Participants"}, {"arrows": "to", "from": "NCT04544293", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline to Week 49"}, {"arrows": "to", "from": "NCT04544293", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline to 28 days"}, {"arrows": "to", "from": "NCT04544293", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "SGRQ Activity component score"}, {"arrows": "to", "from": "NCT04544293", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "St. George\u0027s Hospital Respiratory Questionnaire"}, {"arrows": "to", "from": "NCT04544293", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change from baseline in Peak FEV1 response"}, {"arrows": "to", "from": "NCT04544293", "label": "EVALUATES", "title": "EVALUATES", "to": "Inhaled Molgramostim Nebulizer Solution"}, {"arrows": "to", "from": "NCT04544293", "label": "INVOLVES", "title": "INVOLVES", "to": "Idiopathic Pulmonary Fibrosis"}, {"arrows": "to", "from": "NCT03181893", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline to Week 49"}, {"arrows": "to", "from": "NCT03181893", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Treatment-Emergent SAEs"}, {"arrows": "to", "from": "NCT03181893", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "CDASI score change"}, {"arrows": "to", "from": "NCT03181893", "label": "EVALUATES", "title": "EVALUATES", "to": "Intravenous Sabirnetug"}, {"arrows": "to", "from": "NCT03181893", "label": "INVOLVES", "title": "INVOLVES", "to": "Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score"}, {"arrows": "to", "from": "NCT01328093", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline condition"}, {"arrows": "to", "from": "NCT01328093", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Simpson Angus Rating Scale"}, {"arrows": "to", "from": "NCT01328093", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Barnes Akathisia Rating Scale"}, {"arrows": "to", "from": "NCT01328093", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change in weight control"}, {"arrows": "to", "from": "NCT01328093", "label": "EVALUATES", "title": "EVALUATES", "to": "Iloperidone"}, {"arrows": "to", "from": "NCT01328093", "label": "EVALUATES", "title": "EVALUATES", "to": "LY2624803"}, {"arrows": "to", "from": "NCT01328093", "label": "INVOLVES", "title": "INVOLVES", "to": "Early-Episode Schizophrenia"}, {"arrows": "to", "from": "NCT04732793", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "WOMAC A"}, {"arrows": "to", "from": "NCT04732793", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "baseline through 16 weeks"}, {"arrows": "to", "from": "NCT04732793", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "WOMAC B Stiffness"}, {"arrows": "to", "from": "NCT04732793", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "WOMAC A subscale"}, {"arrows": "to", "from": "NCT04732793", "label": "EVALUATES", "title": "EVALUATES", "to": "Hyruan ONE"}, {"arrows": "to", "from": "NCT04732793", "label": "INVOLVES", "title": "INVOLVES", "to": "Osteoarthritis-related Pain"}, {"arrows": "to", "from": "NCT02240693", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change From Baseline-2"}, {"arrows": "to", "from": "NCT02240693", "label": "INVOLVES", "title": "INVOLVES", "to": "Early Symptomatic Alzheimer\u0027s Disease"}, {"arrows": "to", "from": "NCT02240693", "label": "EVALUATES", "title": "EVALUATES", "to": "BI 456906"}, {"arrows": "to", "from": "NCT02240693", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "self care and daily function"}, {"arrows": "to", "from": "NCT02240693", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "ADCS-ADL scale"}, {"arrows": "to", "from": "NCT06456593", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "SES-CD ulcer subscore \u003e 1"}, {"arrows": "to", "from": "NCT06456593", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "endoscopic treatment improvement"}, {"arrows": "to", "from": "NCT06456593", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Clinically Significant Remission"}, {"arrows": "to", "from": "NCT06456593", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "CDAI-Defined Clinical Response"}, {"arrows": "to", "from": "NCT06456593", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "CDASI score change"}, {"arrows": "to", "from": "NCT06456593", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Weeks 12"}, {"arrows": "to", "from": "NCT06456593", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Week 60"}, {"arrows": "to", "from": "NCT06456593", "label": "EVALUATES", "title": "EVALUATES", "to": "Obefazimod"}, {"arrows": "to", "from": "NCT06456593", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "PRO-2 Remission"}, {"arrows": "to", "from": "NCT06456593", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Mayo IBD symptom severity score"}, {"arrows": "to", "from": "NCT06456593", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Simple Endoscopic Score for Crohn\u0027s disease (SES-CD)"}, {"arrows": "to", "from": "NCT06456593", "label": "INVOLVES", "title": "INVOLVES", "to": "Immune-related Colitis"}, {"arrows": "to", "from": "NCT05590793", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in electrocardiograms"}, {"arrows": "to", "from": "NCT05590793", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Serum Testosterone Levels"}, {"arrows": "to", "from": "NCT05590793", "label": "EVALUATES", "title": "EVALUATES", "to": "Triptorelin Pamoate PR 3-month"}, {"arrows": "to", "from": "NCT05590793", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Chinese Adult Subjects"}, {"arrows": "to", "from": "NCT05590793", "label": "INVOLVES", "title": "INVOLVES", "to": "Advanced Prostate Cancer"}, {"arrows": "to", "from": "NCT05590793", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "physical examination results"}, {"arrows": "to", "from": "NCT05590793", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Prostate-Specific Antigen Levels"}, {"arrows": "to", "from": "NCT05590793", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Clinically significant abnormalities in vital signs"}, {"arrows": "to", "from": "NCT05590793", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Screening laboratory parameters"}, {"arrows": "to", "from": "NCT05590793", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Treatment-Emergent SAEs"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Overall platelet response"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "RBC"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "IGA cleared or minimal"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Urea Nitrogen"}, {"arrows": "to", "from": "NCT05732454", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "oral medications"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Mean Change Total Bilirubin"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "mean corpuscular hemoglobin"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "TBNK panel"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "WBC"}, {"arrows": "to", "from": "NCT05732454", "label": "INVOLVES", "title": "INVOLVES", "to": "Children with atopic dermatitis"}, {"arrows": "to", "from": "NCT05732454", "label": "EVALUATES", "title": "EVALUATES", "to": "Oral Etrasimod"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Serum creatinine \u22643 mg/dL"}, {"arrows": "to", "from": "NCT05732454", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Hematocrit change"}, {"arrows": "to", "from": "NCT02220933", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "EDSS or TW25"}, {"arrows": "to", "from": "NCT02220933", "label": "INVOLVES", "title": "INVOLVES", "to": "Disease duration of secondary progressive multiple sclerosis"}, {"arrows": "to", "from": "NCT02220933", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "MSWS"}, {"arrows": "to", "from": "NCT02220933", "label": "EVALUATES", "title": "EVALUATES", "to": "MD1003"}, {"arrows": "to", "from": "NCT02220933", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "decreased EDSS"}, {"arrows": "to", "from": "NCT03836287", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Hyperhidrosis severity 3 or 4"}, {"arrows": "to", "from": "NCT03836287", "label": "EVALUATES", "title": "EVALUATES", "to": "Sofpironium Bromide Gel"}, {"arrows": "to", "from": "NCT03836287", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Gravimetrically Measured Sweat Production"}, {"arrows": "to", "from": "NCT03836287", "label": "INVOLVES", "title": "INVOLVES", "to": "Primary Axillary Hyperhidrosis"}, {"arrows": "to", "from": "NCT03836287", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Up to 32 weeks"}, {"arrows": "to", "from": "NCT03068754", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Clinically Significant Response"}, {"arrows": "to", "from": "NCT03068754", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Lung function parameters"}, {"arrows": "to", "from": "NCT03068754", "label": "EVALUATES", "title": "EVALUATES", "to": "Acthar Gel"}, {"arrows": "to", "from": "NCT03068754", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Rasch Overall ALS Disability Scale"}, {"arrows": "to", "from": "NCT03068754", "label": "INVOLVES", "title": "INVOLVES", "to": "ALS or MS"}, {"arrows": "to", "from": "NCT06272487", "label": "INVOLVES", "title": "INVOLVES", "to": "Diagnosis of severe hypertension"}, {"arrows": "to", "from": "NCT06272487", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change From Baseline-2"}, {"arrows": "to", "from": "NCT06272487", "label": "EVALUATES", "title": "EVALUATES", "to": "Zilebesiran"}, {"arrows": "to", "from": "NCT06272487", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Standard of Care"}, {"arrows": "to", "from": "NCT06272487", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Percent Change from Baseline in Serum Angiotensinogen"}, {"arrows": "to", "from": "NCT02438787", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "ASAS20 treatment response"}, {"arrows": "to", "from": "NCT02438787", "label": "INVOLVES", "title": "INVOLVES", "to": "Prior Anti-TNF Therapy"}, {"arrows": "to", "from": "NCT02438787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Early Spondyloarthritis"}, {"arrows": "to", "from": "NCT02438787", "label": "EVALUATES", "title": "EVALUATES", "to": "Abrilumab"}, {"arrows": "to", "from": "NCT02438787", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "ASAS40 treatment response"}, {"arrows": "to", "from": "NCT04053387", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Median Time to Improvement"}, {"arrows": "to", "from": "NCT04053387", "label": "INVOLVES", "title": "INVOLVES", "to": "at least one psoriatic plaque"}, {"arrows": "to", "from": "NCT04053387", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "sPGA (0)"}, {"arrows": "to", "from": "NCT04053387", "label": "EVALUATES", "title": "EVALUATES", "to": "VTAMA (Tapinarof) Cream"}, {"arrows": "to", "from": "NCT04053387", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Potentially Clinically Important Changes"}, {"arrows": "to", "from": "NCT05002933", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Adults \u003e=12 years old"}, {"arrows": "to", "from": "NCT05002933", "label": "INVOLVES", "title": "INVOLVES", "to": "Overweight and Obese Subjects With Type 2 Diabetes"}, {"arrows": "to", "from": "NCT05002933", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Percentage of Participants Achieving a Therapeutic Glycemic Response"}, {"arrows": "to", "from": "NCT05002933", "label": "EVALUATES", "title": "EVALUATES", "to": "Insulin Glargine/Lixisenatide Fixed Ratio Combination"}, {"arrows": "to", "from": "NCT05002933", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Adjusted Mean Change HbA1c"}, {"arrows": "to", "from": "NCT05426733", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change mid-arm circumference"}, {"arrows": "to", "from": "NCT05426733", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change serum bile acids"}, {"arrows": "to", "from": "NCT05426733", "label": "INVOLVES", "title": "INVOLVES", "to": "Primary Biliary Cholangitis"}, {"arrows": "to", "from": "NCT05426733", "label": "EVALUATES", "title": "EVALUATES", "to": "Odevixibat"}, {"arrows": "to", "from": "NCT05426733", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in Fibrosis-4 (FIB-4) Score"}, {"arrows": "to", "from": "NCT05426733", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change pediatric end-stage liver disease score"}, {"arrows": "to", "from": "NCT05426733", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change AST to platelet ratio index"}, {"arrows": "to", "from": "NCT05426733", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Proportion alive"}, {"arrows": "to", "from": "NCT05426733", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in weight control"}, {"arrows": "to", "from": "NCT05426733", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Completion of 104-week Treatment Period"}, {"arrows": "to", "from": "NCT05426733", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Patient\u0027s written informed consent"}, {"arrows": "to", "from": "NCT05426733", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change height"}, {"arrows": "to", "from": "NCT05426733", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Time to onset sentinel events"}, {"arrows": "to", "from": "NCT04437433", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Columbia Suicide Severity Rating Scale"}, {"arrows": "to", "from": "NCT04437433", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Treatment-Emergent SAEs"}, {"arrows": "to", "from": "NCT04437433", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Number of patients with clinically significant changes in vital signs"}, {"arrows": "to", "from": "NCT04437433", "label": "INVOLVES", "title": "INVOLVES", "to": "Migraine Headaches"}, {"arrows": "to", "from": "NCT04437433", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Clinically significant abnormalities in clinical laboratory values"}, {"arrows": "to", "from": "NCT04437433", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Completed all visits"}, {"arrows": "to", "from": "NCT04437433", "label": "EVALUATES", "title": "EVALUATES", "to": "Oral Atogepant"}, {"arrows": "to", "from": "NCT04437433", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Clinically significant abnormalities in ECG"}, {"arrows": "to", "from": "NCT04479787", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Responder Rate PGIC"}, {"arrows": "to", "from": "NCT04479787", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "NRS mean change"}, {"arrows": "to", "from": "NCT04479787", "label": "INVOLVES", "title": "INVOLVES", "to": "Change in Back Pain"}, {"arrows": "to", "from": "NCT04479787", "label": "EVALUATES", "title": "EVALUATES", "to": "10 kHz Spinal Cord Stimulation"}, {"arrows": "to", "from": "NCT04479787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "\u2265 30% decrease from baseline"}, {"arrows": "to", "from": "NCT04479787", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in OSDI"}, {"arrows": "to", "from": "NCT04479787", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Study Composite Responder"}, {"arrows": "to", "from": "NCT04479787", "label": "EVALUATES", "title": "EVALUATES", "to": "Medical Management"}, {"arrows": "to", "from": "NCT00327587", "label": "EVALUATES", "title": "EVALUATES", "to": "Olmesartan and Amlodipine"}, {"arrows": "to", "from": "NCT00327587", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Systolic BP control"}, {"arrows": "to", "from": "NCT00327587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Diastolic BP \u226590 mmHg"}, {"arrows": "to", "from": "NCT00327587", "label": "INVOLVES", "title": "INVOLVES", "to": "Diagnosis of severe hypertension"}, {"arrows": "to", "from": "NCT00327587", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Normalized blood pressure"}, {"arrows": "to", "from": "NCT00327587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Systolic BP \u2265140 mmHg"}, {"arrows": "to", "from": "NCT00327587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Diastolic BP \u226580 mmHg"}, {"arrows": "to", "from": "NCT00327587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Arm circumference \u003e 42 cm"}, {"arrows": "to", "from": "NCT00327587", "label": "EVALUATES", "title": "EVALUATES", "to": "Amlodipine Besylate/Benazepril"}, {"arrows": "to", "from": "NCT00327587", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Diastolic blood pressure \u003c 60 mm Hg"}, {"arrows": "to", "from": "NCT00327587", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Diastolic blood pressure \u003c 60 mm Hg"}, {"arrows": "to", "from": "NCT00327587", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Systolic BP control"}, {"arrows": "to", "from": "NCT00327587", "label": "EVALUATES", "title": "EVALUATES", "to": "HCTZ 25 mg"}, {"arrows": "to", "from": "NCT02618187", "label": "INVOLVES", "title": "INVOLVES", "to": "Duration of Ulcerative Colitis"}, {"arrows": "to", "from": "NCT02618187", "label": "EVALUATES", "title": "EVALUATES", "to": "SER-214"}, {"arrows": "to", "from": "NCT02618187", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Microbiota composition analysis"}, {"arrows": "to", "from": "NCT02618187", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Participants in Remission"}, {"arrows": "to", "from": "NCT02618187", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "9-point modified Mayo score"}, {"arrows": "to", "from": "NCT01429987", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "stool frequency evaluation"}, {"arrows": "to", "from": "NCT01429987", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "18 to 55 years old"}, {"arrows": "to", "from": "NCT01429987", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "BMI 18 to 32 kg/m2"}, {"arrows": "to", "from": "NCT01429987", "label": "EVALUATES", "title": "EVALUATES", "to": "Plecanatide"}, {"arrows": "to", "from": "NCT01429987", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "12-week CSBM Frequency"}, {"arrows": "to", "from": "NCT01429987", "label": "INVOLVES", "title": "INVOLVES", "to": "IBS-Constipation"}, {"arrows": "to", "from": "NCT01429987", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Straining Score"}, {"arrows": "to", "from": "NCT01429987", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "ROME IV criteria"}, {"arrows": "to", "from": "NCT04158687", "label": "EVALUATES", "title": "EVALUATES", "to": "CP-601"}, {"arrows": "to", "from": "NCT04158687", "label": "INVOLVES", "title": "INVOLVES", "to": "Early-Episode Schizophrenia"}, {"arrows": "to", "from": "NCT04158687", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Adults \u003e=12 years old"}, {"arrows": "to", "from": "NCT04158687", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Total Personal and Social Performance"}, {"arrows": "to", "from": "NCT04158687", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "CGI-Severity Score"}, {"arrows": "to", "from": "NCT04158687", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change From Baseline-2"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "regular alcohol consumption"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "clinically significant changes in Electrocardiogram readings"}, {"arrows": "to", "from": "NCT01862887", "label": "EVALUATES", "title": "EVALUATES", "to": "PF-07038124"}, {"arrows": "to", "from": "NCT01862887", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Fmax"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Healthy adult male subjects"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Healthy male or female"}, {"arrows": "to", "from": "NCT01862887", "label": "INVOLVES", "title": "INVOLVES", "to": "QTcB change"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "clinically significant respiratory"}, {"arrows": "to", "from": "NCT01862887", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Time for Cmax"}, {"arrows": "to", "from": "NCT01862887", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "QTcB change"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "clinically significant allergic disease"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "severe renal involvement at Screening"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Total Fat Mass"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "endocrine abnormalities"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "psychiatric disease"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Mean change in BMI"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "hepatic dysfunction"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "neurological disorder"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "positive urine drug screen"}, {"arrows": "to", "from": "NCT01862887", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "AUC from time zero"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Clinically significant haematology assessment abnormalities"}, {"arrows": "to", "from": "NCT01862887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "gastrointestinal abnormalities"}, {"arrows": "to", "from": "NCT00397033", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "PANSS General Psychopathology Subscale"}, {"arrows": "to", "from": "NCT00397033", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "PANSS General Psychopathology Subscale"}, {"arrows": "to", "from": "NCT00397033", "label": "INVOLVES", "title": "INVOLVES", "to": "psychiatric disease"}, {"arrows": "to", "from": "NCT00397033", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Greater Than 50% Reduction"}, {"arrows": "to", "from": "NCT00397033", "label": "EVALUATES", "title": "EVALUATES", "to": "Oral Paliperidone Extended-Release"}, {"arrows": "to", "from": "NCT04172233", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "mPASI-90"}, {"arrows": "to", "from": "NCT04172233", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "PASI \u2265 12 points"}, {"arrows": "to", "from": "NCT04172233", "label": "EVALUATES", "title": "EVALUATES", "to": "AKST1210"}, {"arrows": "to", "from": "NCT04172233", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in Physician\u0027s Global Assessment"}, {"arrows": "to", "from": "NCT04172233", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "mPASI-75"}, {"arrows": "to", "from": "NCT04172233", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "10% body surface areas"}, {"arrows": "to", "from": "NCT04172233", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Physician\u0027s global assessment scores"}, {"arrows": "to", "from": "NCT04172233", "label": "INVOLVES", "title": "INVOLVES", "to": "at least one psoriatic plaque"}, {"arrows": "to", "from": "NCT05522387", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change From Baseline-2"}, {"arrows": "to", "from": "NCT05522387", "label": "INVOLVES", "title": "INVOLVES", "to": "Early Symptomatic Alzheimer\u0027s Disease"}, {"arrows": "to", "from": "NCT05522387", "label": "EVALUATES", "title": "EVALUATES", "to": "XPro1595"}, {"arrows": "to", "from": "NCT05522387", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Clinical Dementia Rating-Sum of Boxes"}, {"arrows": "to", "from": "NCT05522387", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "predefined criteria"}, {"arrows": "to", "from": "NCT00848354", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "ACR20 Responders"}, {"arrows": "to", "from": "NCT00848354", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "HAI Score"}, {"arrows": "to", "from": "NCT00848354", "label": "EVALUATES", "title": "EVALUATES", "to": "Etokimab"}, {"arrows": "to", "from": "NCT00848354", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "SF36 Score"}, {"arrows": "to", "from": "NCT00848354", "label": "INVOLVES", "title": "INVOLVES", "to": "arthritis pain"}, {"arrows": "to", "from": "NCT00848354", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline to 28 days"}, {"arrows": "to", "from": "NCT02674633", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "ADHD-RS-IV Scores"}, {"arrows": "to", "from": "NCT02674633", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "TOVA API"}, {"arrows": "to", "from": "NCT02674633", "label": "EVALUATES", "title": "EVALUATES", "to": "Software"}, {"arrows": "to", "from": "NCT02674633", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "DSM-5 diagnostic criteria"}, {"arrows": "to", "from": "NCT02674633", "label": "INVOLVES", "title": "INVOLVES", "to": "ADHD-RS change"}, {"arrows": "to", "from": "NCT00886587", "label": "EVALUATES", "title": "EVALUATES", "to": "device intervention"}, {"arrows": "to", "from": "NCT00886587", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "EASI score at Week 48"}, {"arrows": "to", "from": "NCT00886587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Able to provide informed consent"}, {"arrows": "to", "from": "NCT00886587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Diagnosis of AD/ADRD"}, {"arrows": "to", "from": "NCT00886587", "label": "INVOLVES", "title": "INVOLVES", "to": "Children with atopic dermatitis"}, {"arrows": "to", "from": "NCT00886587", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Itch Score Day 43"}, {"arrows": "to", "from": "NCT00886587", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "IGADA Score Day 43"}, {"arrows": "to", "from": "NCT00886587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Post-menarchal female"}, {"arrows": "to", "from": "NCT00886587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "negative urine pregnancy test result"}, {"arrows": "to", "from": "NCT05054387", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "eGFR \u003e 60 ml/min/1.73 m2"}, {"arrows": "to", "from": "NCT05054387", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "12 years or older"}, {"arrows": "to", "from": "NCT05054387", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "plasma or leukocyte \u03b1GAL activity deficient"}, {"arrows": "to", "from": "NCT05054387", "label": "EVALUATES", "title": "EVALUATES", "to": "Fabrazyme"}, {"arrows": "to", "from": "NCT05054387", "label": "INVOLVES", "title": "INVOLVES", "to": "diagnosed with Fabry disease"}, {"arrows": "to", "from": "NCT05054387", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "change of Fabry disease symptoms"}, {"arrows": "to", "from": "NCT05054387", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "diagnosed with Fabry disease"}, {"arrows": "to", "from": "NCT05054387", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "naive to agalsidase beta"}, {"arrows": "to", "from": "NCT04360187", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Treatment-Emergent SAEs"}, {"arrows": "to", "from": "NCT04360187", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Serious AEs"}, {"arrows": "to", "from": "NCT04360187", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "ages 2 years and older"}, {"arrows": "to", "from": "NCT04360187", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Eczema Area and Severity Index (EASI) of \u226512 and \\\u003c48"}, {"arrows": "to", "from": "NCT04360187", "label": "EVALUATES", "title": "EVALUATES", "to": "Crisaborole"}, {"arrows": "to", "from": "NCT04360187", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Clinically Significant Response"}, {"arrows": "to", "from": "NCT04360187", "label": "INVOLVES", "title": "INVOLVES", "to": "Children with atopic dermatitis"}, {"arrows": "to", "from": "NCT00678587", "label": "INVOLVES", "title": "INVOLVES", "to": "Thrombocytopenia"}, {"arrows": "to", "from": "NCT00678587", "label": "INVOLVES", "title": "INVOLVES", "to": "Hepatobiliary fibrosis"}, {"arrows": "to", "from": "NCT00678587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "platelet count \u2265 100"}, {"arrows": "to", "from": "NCT00678587", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in bleeding score"}, {"arrows": "to", "from": "NCT00678587", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Platelet transfusion independence"}, {"arrows": "to", "from": "NCT00678587", "label": "EVALUATES", "title": "EVALUATES", "to": "Switched to eltrombopag or romiplostim"}, {"arrows": "to", "from": "NCT01098487", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Collagen Level"}, {"arrows": "to", "from": "NCT01098487", "label": "EVALUATES", "title": "EVALUATES", "to": "Switched to eltrombopag or romiplostim"}, {"arrows": "to", "from": "NCT01098487", "label": "INVOLVES", "title": "INVOLVES", "to": "Chronic Immune Thrombocytopenic Purpura"}, {"arrows": "to", "from": "NCT01098487", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "MF Grade change"}, {"arrows": "to", "from": "NCT01098487", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "centrally-reviewed BM biopsy"}, {"arrows": "to", "from": "NCT03772587", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Day 1 up to 393"}, {"arrows": "to", "from": "NCT03772587", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Number of Participants Reporting TEAEs"}, {"arrows": "to", "from": "NCT03772587", "label": "INVOLVES", "title": "INVOLVES", "to": "Lambert Eaton Myasthenic Syndrome"}, {"arrows": "to", "from": "NCT03772587", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Number of SAEs"}, {"arrows": "to", "from": "NCT03772587", "label": "EVALUATES", "title": "EVALUATES", "to": "M2951"}, {"arrows": "to", "from": "NCT03772587", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Number of participants with AESI"}, {"arrows": "to", "from": "NCT00876187", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Daily LBPI Score"}, {"arrows": "to", "from": "NCT00876187", "label": "INVOLVES", "title": "INVOLVES", "to": "Chronic Low-Back Pain"}, {"arrows": "to", "from": "NCT00876187", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline Observation Carried Forward"}, {"arrows": "to", "from": "NCT00876187", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Patient Global Improvement"}, {"arrows": "to", "from": "NCT00876187", "label": "EVALUATES", "title": "EVALUATES", "to": "Subcutaneous Tanezumab"}, {"arrows": "to", "from": "NCT00876187", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "QMG Total Score"}, {"arrows": "to", "from": "NCT00660387", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change From Baseline-2"}, {"arrows": "to", "from": "NCT00660387", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Levodopa/Carbidopa/Entacapone"}, {"arrows": "to", "from": "NCT00660387", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Average Daily Normalized \"Off\" Time"}, {"arrows": "to", "from": "NCT00660387", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Average Daily Normalized \"On\" Time"}, {"arrows": "to", "from": "NCT00660387", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change From Baseline-2"}, {"arrows": "to", "from": "NCT00660387", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change From Baseline in Parkinson\u0027s Disease Questionnaire-39 Summary Index Score"}, {"arrows": "to", "from": "NCT00660387", "label": "INVOLVES", "title": "INVOLVES", "to": "early-stage Parkinson\u0027s disease"}, {"arrows": "to", "from": "NCT00660387", "label": "EVALUATES", "title": "EVALUATES", "to": "Levodopa/Carbidopa/Entacapone"}, {"arrows": "to", "from": "NCT01255787", "label": "INVOLVES", "title": "INVOLVES", "to": "Major Depressive Disorder With Mixed Features"}, {"arrows": "to", "from": "NCT01255787", "label": "EVALUATES", "title": "EVALUATES", "to": "Suvorexant"}, {"arrows": "to", "from": "NCT01255787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline value"}, {"arrows": "to", "from": "NCT01255787", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "CGI-C Scale Scores"}, {"arrows": "to", "from": "NCT01255787", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "MADRS Response Rate"}, {"arrows": "to", "from": "NCT01255787", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "MADRS total score \u226522"}, {"arrows": "to", "from": "NCT01255787", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "MADRS Remission at Week 8"}, {"arrows": "to", "from": "NCT00877487", "label": "EVALUATES", "title": "EVALUATES", "to": "Concerta"}, {"arrows": "to", "from": "NCT00877487", "label": "INVOLVES", "title": "INVOLVES", "to": "documented ADHD diagnosis"}, {"arrows": "to", "from": "NCT00877487", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Documented history of ADHD diagnosis"}, {"arrows": "to", "from": "NCT00877487", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "18 to 55 years old"}, {"arrows": "to", "from": "NCT00877487", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "CGI-C Scale Scores"}, {"arrows": "to", "from": "NCT00877487", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "negative urine pregnancy test result"}, {"arrows": "to", "from": "NCT00877487", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "ADHD-RS-IV Scores"}, {"arrows": "to", "from": "NCT00877487", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "CGI-C Scale Scores"}, {"arrows": "to", "from": "NCT00877487", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "ADHD-RS-IV Scores"}, {"arrows": "to", "from": "NCT00877487", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "stable SPD489 treatment 6 months"}, {"arrows": "to", "from": "NCT01524887", "label": "INVOLVES", "title": "INVOLVES", "to": "Early Symptomatic Alzheimer\u0027s Disease"}, {"arrows": "to", "from": "NCT01524887", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in ADCS-ADL"}, {"arrows": "to", "from": "NCT01524887", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "ADCS-ADL scale"}, {"arrows": "to", "from": "NCT01524887", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline to \u226420 weeks"}, {"arrows": "to", "from": "NCT01524887", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "ADAS-Cog-11 Scores"}, {"arrows": "to", "from": "NCT01524887", "label": "EVALUATES", "title": "EVALUATES", "to": "IGIV"}, {"arrows": "to", "from": "NCT01524887", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Neuropsychiatry Inventory"}, {"arrows": "to", "from": "NCT01617187", "label": "EVALUATES", "title": "EVALUATES", "to": "Pimavanserin"}, {"arrows": "to", "from": "NCT01617187", "label": "INVOLVES", "title": "INVOLVES", "to": "Early-Episode Schizophrenia"}, {"arrows": "to", "from": "NCT01617187", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "CGI-C Scale Scores"}, {"arrows": "to", "from": "NCT01617187", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "PANSS Responders"}, {"arrows": "to", "from": "NCT01617187", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change From Baseline-2"}, {"arrows": "to", "from": "NCT01617187", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline to 28 days"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "DSM-5 diagnostic criteria"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "CGI-Severity Score"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "no prior lurasidone trial"}, {"arrows": "to", "from": "NCT03465787", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "PANSS General Psychopathology Subscale"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "switched from other antipsychotic drugs"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "age 18 or above and below 65"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "no drug abuse"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "no chronic CNS disease"}, {"arrows": "to", "from": "NCT03465787", "label": "EVALUATES", "title": "EVALUATES", "to": "Iloperidone"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "no pregnancy or breastfeeding"}, {"arrows": "to", "from": "NCT03465787", "label": "INVOLVES", "title": "INVOLVES", "to": "Early-Episode Schizophrenia"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "reasonably good health"}, {"arrows": "to", "from": "NCT03465787", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "CGI-C Scale Scores"}, {"arrows": "to", "from": "NCT03465787", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "able to cooperate"}, {"arrows": "to", "from": "NCT05865496", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "UPSIT Score"}, {"arrows": "to", "from": "NCT05865496", "label": "EVALUATES", "title": "EVALUATES", "to": "611"}, {"arrows": "to", "from": "NCT05865496", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Nasal blockade/obstruction/congestion"}, {"arrows": "to", "from": "NCT05865496", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Lysholm Score"}, {"arrows": "to", "from": "NCT05865496", "label": "INVOLVES", "title": "INVOLVES", "to": "Nasal polyp score \u2265 4"}, {"arrows": "to", "from": "NCT05865496", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Up to 48 weeks"}, {"arrows": "to", "from": "NCT05865496", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Nasal polyp score \u2265 4"}, {"arrows": "to", "from": "NCT05865496", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Bilateral NPS"}, {"arrows": "to", "from": "NCT03909516", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Average Evening Pain Intensity"}, {"arrows": "to", "from": "NCT03909516", "label": "EVALUATES", "title": "EVALUATES", "to": "Iovera\u00b0 Device"}, {"arrows": "to", "from": "NCT03909516", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Single Assessment Numerical Evaluation"}, {"arrows": "to", "from": "NCT03909516", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline to 28 days"}, {"arrows": "to", "from": "NCT03909516", "label": "INVOLVES", "title": "INVOLVES", "to": "Lateral Ankle Ligament Reconstruction"}, {"arrows": "to", "from": "NCT03909516", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Area-Under-Effect"}, {"arrows": "to", "from": "NCT03909516", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline to 10 days post-surgery"}, {"arrows": "to", "from": "NCT03909516", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Oxford Knee Score"}, {"arrows": "to", "from": "NCT03836716", "label": "INVOLVES", "title": "INVOLVES", "to": "ALS or MS"}, {"arrows": "to", "from": "NCT03836716", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Hematology Screening parameters"}, {"arrows": "to", "from": "NCT03836716", "label": "EVALUATES", "title": "EVALUATES", "to": "Aramchol Meglumine"}, {"arrows": "to", "from": "NCT03836716", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Mean Change EASI"}, {"arrows": "to", "from": "NCT03836716", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "IMP dose"}, {"arrows": "to", "from": "NCT02111096", "label": "INVOLVES", "title": "INVOLVES", "to": "Overweight and Obese Subjects With Type 2 Diabetes"}, {"arrows": "to", "from": "NCT02111096", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Fasting and Post meal Glucose"}, {"arrows": "to", "from": "NCT02111096", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "ALT and AST elevation"}, {"arrows": "to", "from": "NCT02111096", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "hepatic fat fraction \u2265 5%"}, {"arrows": "to", "from": "NCT02111096", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Fasting Triglyceride Levels"}, {"arrows": "to", "from": "NCT02111096", "label": "EVALUATES", "title": "EVALUATES", "to": "LY2624803"}, {"arrows": "to", "from": "NCT02111096", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Baseline Weight"}, {"arrows": "to", "from": "NCT02111096", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Hemoglobin A1c Levels"}, {"arrows": "to", "from": "NCT02046616", "label": "INVOLVES", "title": "INVOLVES", "to": "arthritis pain"}, {"arrows": "to", "from": "NCT02046616", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change from Baseline in DAS28-CRP"}, {"arrows": "to", "from": "NCT02046616", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "methotrexate-inadequate responders"}, {"arrows": "to", "from": "NCT02046616", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 30% Response"}, {"arrows": "to", "from": "NCT02046616", "label": "EVALUATES", "title": "EVALUATES", "to": "Tocilizumab Subcutaneous"}, {"arrows": "to", "from": "NCT01647516", "label": "INVOLVES", "title": "INVOLVES", "to": "Duration of Ulcerative Colitis"}, {"arrows": "to", "from": "NCT01647516", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "9-point modified Mayo score"}, {"arrows": "to", "from": "NCT01647516", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Participants in Remission"}, {"arrows": "to", "from": "NCT01647516", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Clinical Response 100"}, {"arrows": "to", "from": "NCT01647516", "label": "EVALUATES", "title": "EVALUATES", "to": "Ozarelix"}, {"arrows": "to", "from": "NCT01058096", "label": "EVALUATES", "title": "EVALUATES", "to": "Aripiprazole Lauroxil"}, {"arrows": "to", "from": "NCT01058096", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Able to provide informed consent"}, {"arrows": "to", "from": "NCT01058096", "label": "INVOLVES", "title": "INVOLVES", "to": "Adults With Bipolar I Disorder"}, {"arrows": "to", "from": "NCT01058096", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "YMRS score"}, {"arrows": "to", "from": "NCT01058096", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "CGI-Improvement Score"}, {"arrows": "to", "from": "NCT02317016", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "AUC of Rosuvastatin"}, {"arrows": "to", "from": "NCT02317016", "label": "EVALUATES", "title": "EVALUATES", "to": "AZD9668"}, {"arrows": "to", "from": "NCT02317016", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "tmax of rosuvastatin"}, {"arrows": "to", "from": "NCT02317016", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Maximally Tolerated Statin"}, {"arrows": "to", "from": "NCT02317016", "label": "INVOLVES", "title": "INVOLVES", "to": "Metastatic Non-squamous Non-Small-Cell Lung Cancer"}, {"arrows": "to", "from": "NCT04839016", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "inadequately controlled by topical treatment"}, {"arrows": "to", "from": "NCT04839016", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "PASI-75 Score"}, {"arrows": "to", "from": "NCT04839016", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "sPGA of Clear or Almost Clear at Week 16"}, {"arrows": "to", "from": "NCT04839016", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "disease inadequately controlled"}, {"arrows": "to", "from": "NCT04839016", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "12 years or older"}, {"arrows": "to", "from": "NCT04839016", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "BMI 18 to 32 kg/m2"}, {"arrows": "to", "from": "NCT04839016", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "inadequate topical response"}, {"arrows": "to", "from": "NCT04839016", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "BSA score \u2265 10%"}, {"arrows": "to", "from": "NCT04839016", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "PASI-75 at Week 24"}, {"arrows": "to", "from": "NCT04839016", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Mild to Severe Plaque Psoriasis"}, {"arrows": "to", "from": "NCT04839016", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "sPGA score \u2265 3 points"}, {"arrows": "to", "from": "NCT04839016", "label": "INVOLVES", "title": "INVOLVES", "to": "at least one psoriatic plaque"}, {"arrows": "to", "from": "NCT04839016", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "PASI-75 at Week 24"}, {"arrows": "to", "from": "NCT04839016", "label": "EVALUATES", "title": "EVALUATES", "to": "SHR0302"}, {"arrows": "to", "from": "NCT03971422", "label": "INVOLVES", "title": "INVOLVES", "to": "Lambert Eaton Myasthenic Syndrome"}, {"arrows": "to", "from": "NCT03971422", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change From Baseline-2"}, {"arrows": "to", "from": "NCT03971422", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline up to Day 21"}, {"arrows": "to", "from": "NCT03971422", "label": "EVALUATES", "title": "EVALUATES", "to": "Romosozumab"}, {"arrows": "to", "from": "NCT03971422", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Percentage of Participants Achieving MG-ADL Response"}, {"arrows": "to", "from": "NCT03845075", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Liver function parameters"}, {"arrows": "to", "from": "NCT03845075", "label": "EVALUATES", "title": "EVALUATES", "to": "Metoprolol Succinate Prolonged-Release Tablet"}, {"arrows": "to", "from": "NCT03845075", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Diastolic blood pressure \u003c 60 mm Hg"}, {"arrows": "to", "from": "NCT03845075", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Systolic BP control"}, {"arrows": "to", "from": "NCT03845075", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Treatment-Emergent SAEs"}, {"arrows": "to", "from": "NCT03845075", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Number of Participants With Any Treatment-Emergent Adverse Events"}, {"arrows": "to", "from": "NCT03845075", "label": "INVOLVES", "title": "INVOLVES", "to": "Acquired Hypothalamic Obesity"}, {"arrows": "to", "from": "NCT03845075", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change from Baseline in Average Heart Rate"}, {"arrows": "to", "from": "NCT03845075", "label": "EVALUATES", "title": "EVALUATES", "to": "Tesofensine"}, {"arrows": "to", "from": "NCT03845075", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Serious AEs"}, {"arrows": "to", "from": "NCT03845075", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Serum Creatinine Elevations"}, {"arrows": "to", "from": "NCT03845075", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Hematology Laboratory Results"}, {"arrows": "to", "from": "NCT04507659", "label": "INVOLVES", "title": "INVOLVES", "to": "Sacroiliitis"}, {"arrows": "to", "from": "NCT04507659", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "\u2265 20%"}, {"arrows": "to", "from": "NCT04507659", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "ASAS20 response at Week 12"}, {"arrows": "to", "from": "NCT04507659", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "ASAS20 response at Week 12"}, {"arrows": "to", "from": "NCT04507659", "label": "EVALUATES", "title": "EVALUATES", "to": "Jaktinib Hydrochloride Tablets"}, {"arrows": "to", "from": "NCT02868359", "label": "INVOLVES", "title": "INVOLVES", "to": "Chronic Low-Back Pain"}, {"arrows": "to", "from": "NCT02868359", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Pain scoring"}, {"arrows": "to", "from": "NCT02868359", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Pain Interference on Sleep"}, {"arrows": "to", "from": "NCT02868359", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Neck Disability Index Score"}, {"arrows": "to", "from": "NCT02868359", "label": "EVALUATES", "title": "EVALUATES", "to": "Lyrica"}, {"arrows": "to", "from": "NCT02868359", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "EuroQol 5 Dimensions 5 Levels"}, {"arrows": "to", "from": "NCT02868359", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Rescue medication consumption"}, {"arrows": "to", "from": "NCT01649375", "label": "EVALUATES", "title": "EVALUATES", "to": "securkinumab"}, {"arrows": "to", "from": "NCT01649375", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Baseline to 28 days"}, {"arrows": "to", "from": "NCT01649375", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "ASAS20 treatment response"}, {"arrows": "to", "from": "NCT01649375", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "high-sensitivity CRP"}, {"arrows": "to", "from": "NCT01649375", "label": "INVOLVES", "title": "INVOLVES", "to": "Sacroiliitis"}, {"arrows": "to", "from": "NCT01649375", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "ASAS40 treatment response"}, {"arrows": "to", "from": "NCT00809159", "label": "INVOLVES", "title": "INVOLVES", "to": "Sacroiliitis"}, {"arrows": "to", "from": "NCT00809159", "label": "EVALUATES", "title": "EVALUATES", "to": "AIN457"}, {"arrows": "to", "from": "NCT00809159", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "ASAS20 treatment response"}, {"arrows": "to", "from": "NCT00809159", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Moderate to severe CD"}, {"arrows": "to", "from": "NCT00809159", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "BASMI Score"}, {"arrows": "to", "from": "NCT00365859", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "screening to week 52/early termination"}, {"arrows": "to", "from": "NCT00365859", "label": "EVALUATES", "title": "EVALUATES", "to": "Iloperidone"}, {"arrows": "to", "from": "NCT00365859", "label": "INVOLVES", "title": "INVOLVES", "to": "Autism Spectrum Disorders"}, {"arrows": "to", "from": "NCT00365859", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Simpson Angus Rating Scale"}, {"arrows": "to", "from": "NCT00365859", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Abnormal Involuntary Movement Scale"}, {"arrows": "to", "from": "NCT04312659", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Participants in Remission"}, {"arrows": "to", "from": "NCT04312659", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Children aged 2-15 years"}, {"arrows": "to", "from": "NCT04312659", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "endoscopic treatment improvement"}, {"arrows": "to", "from": "NCT04312659", "label": "EVALUATES", "title": "EVALUATES", "to": "TA-650(Infliximab)"}, {"arrows": "to", "from": "NCT04312659", "label": "INVOLVES", "title": "INVOLVES", "to": "Immune-related Colitis"}, {"arrows": "to", "from": "NCT04312659", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change From Baseline in Height-for-age Z-score"}, {"arrows": "to", "from": "NCT04312659", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Clinical Response 100"}, {"arrows": "to", "from": "NCT04098575", "label": "INVOLVES", "title": "INVOLVES", "to": "Overweight and Obese Subjects With Type 2 Diabetes"}, {"arrows": "to", "from": "NCT04098575", "label": "EVALUATES", "title": "EVALUATES", "to": "Biphasic Remogliflozin Etabonate"}, {"arrows": "to", "from": "NCT04731675", "label": "EVALUATES", "title": "EVALUATES", "to": "AMX0035"}, {"arrows": "to", "from": "NCT04731675", "label": "INVOLVES", "title": "INVOLVES", "to": "Tenosynovial Giant Cell Tumor of the Knee"}, {"arrows": "to", "from": "NCT04731675", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Treatment-Emergent SAEs"}, {"arrows": "to", "from": "NCT04731675", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "WOMAC physical function sub-score"}, {"arrows": "to", "from": "NCT04731675", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Overall Tumor Response"}, {"arrows": "to", "from": "NCT04731675", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in Active Range of Motion"}, {"arrows": "to", "from": "NCT03881059", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "PASI100 response"}, {"arrows": "to", "from": "NCT03881059", "label": "EVALUATES", "title": "EVALUATES", "to": "BMS-986231"}, {"arrows": "to", "from": "NCT03881059", "label": "INVOLVES", "title": "INVOLVES", "to": "History psoriatic arthritis"}, {"arrows": "to", "from": "NCT03881059", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "ACR20 Responders"}, {"arrows": "to", "from": "NCT03881059", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "tender/painful joint count"}, {"arrows": "to", "from": "NCT04680975", "label": "EVALUATES", "title": "EVALUATES", "to": "Oral Belumosudil"}, {"arrows": "to", "from": "NCT04680975", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Patient Global Improvement"}, {"arrows": "to", "from": "NCT04680975", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in Physician\u0027s Global Assessment"}, {"arrows": "to", "from": "NCT04680975", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "new onset lung fibrosis"}, {"arrows": "to", "from": "NCT04680975", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Percent of the predicted forced expiratory volume over 1 second"}, {"arrows": "to", "from": "NCT04680975", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "current active renal disease"}, {"arrows": "to", "from": "NCT04680975", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "mRSS"}, {"arrows": "to", "from": "NCT04680975", "label": "INVOLVES", "title": "INVOLVES", "to": "Diffuse Systemic Sclerosis"}, {"arrows": "to", "from": "NCT04680975", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "cardiac failure"}, {"arrows": "to", "from": "NCT04680975", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Pulmonary Vascular Disease"}, {"arrows": "to", "from": "NCT04680975", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "SHAQ-DI"}, {"arrows": "to", "from": "NCT04680975", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "ACR CRISS composite score"}, {"arrows": "to", "from": "NCT01603459", "label": "EVALUATES", "title": "EVALUATES", "to": "Onabotulinumtoxin A"}, {"arrows": "to", "from": "NCT01603459", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Ashworth Score"}, {"arrows": "to", "from": "NCT01603459", "label": "INVOLVES", "title": "INVOLVES", "to": "Post-Stroke Upper Limb Spasticity"}, {"arrows": "to", "from": "NCT01603459", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Investigator\u0027s Global Assessment of Efficacy"}, {"arrows": "to", "from": "NCT01603459", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Injection Cycle"}, {"arrows": "to", "from": "NCT00614575", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Modified Barthel Index"}, {"arrows": "to", "from": "NCT00614575", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "UPDRS Part I Item 3 Score"}, {"arrows": "to", "from": "NCT00614575", "label": "INVOLVES", "title": "INVOLVES", "to": "depressed episode"}, {"arrows": "to", "from": "NCT00614575", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "UPDRS Items 32 and 33 Composite Score"}, {"arrows": "to", "from": "NCT00614575", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Bech Melancholia Subscale Score"}, {"arrows": "to", "from": "NCT00614575", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Weeks 12"}, {"arrows": "to", "from": "NCT00614575", "label": "INVOLVES", "title": "INVOLVES", "to": "early-stage Parkinson\u0027s disease"}, {"arrows": "to", "from": "NCT00614575", "label": "EVALUATES", "title": "EVALUATES", "to": "Pramipexole Extended Release"}, {"arrows": "to", "from": "NCT02400775", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Office BP measurements"}, {"arrows": "to", "from": "NCT02400775", "label": "INVOLVES", "title": "INVOLVES", "to": "High LDL-C"}, {"arrows": "to", "from": "NCT02400775", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in Fibrosis-4 (FIB-4) Score"}, {"arrows": "to", "from": "NCT02400775", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Change in lipid-regulating protein levels"}, {"arrows": "to", "from": "NCT02400775", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in calcified component"}, {"arrows": "to", "from": "NCT02400775", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in number of microchannels"}, {"arrows": "to", "from": "NCT02400775", "label": "INVOLVES", "title": "INVOLVES", "to": "Stage II essential hypertension"}, {"arrows": "to", "from": "NCT02400775", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Change in thickness of fibrous cap"}, {"arrows": "to", "from": "NCT02400775", "label": "INVOLVES", "title": "INVOLVES", "to": "No recent unstable angina"}, {"arrows": "to", "from": "NCT02400775", "label": "EVALUATES", "title": "EVALUATES", "to": "Amlodipine Besylate/Benazepril"}, {"arrows": "to", "from": "NCT02698475", "label": "EVALUATES", "title": "EVALUATES", "to": "Abrilumab"}, {"arrows": "to", "from": "NCT02698475", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "C-DLQI Score"}, {"arrows": "to", "from": "NCT02698475", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Failed standard treatment"}, {"arrows": "to", "from": "NCT02698475", "label": "INVOLVES", "title": "INVOLVES", "to": "Mild to Severe Plaque Psoriasis"}, {"arrows": "to", "from": "NCT02698475", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "PGA score clear/almost clear"}, {"arrows": "to", "from": "NCT02698475", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "PASI100 response"}, {"arrows": "to", "from": "NCT01351675", "label": "MEASURES_SECONDARY", "title": "MEASURES_SECONDARY", "to": "Time-to-first event"}, {"arrows": "to", "from": "NCT01351675", "label": "EVALUATES", "title": "EVALUATES", "to": "Bardoxolone Methyl"}, {"arrows": "to", "from": "NCT01351675", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Mean change in Systolic BP"}, {"arrows": "to", "from": "NCT01351675", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "12 years or older"}, {"arrows": "to", "from": "NCT01351675", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Diastolic blood pressure \u003c 60 mm Hg"}, {"arrows": "to", "from": "NCT01351675", "label": "MEASURES_PRIMARY", "title": "MEASURES_PRIMARY", "to": "Time to First Relapse Event"}, {"arrows": "to", "from": "NCT01351675", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Treatment with an ACE inhibitor and/or an ARB"}, {"arrows": "to", "from": "NCT01351675", "label": "INVOLVES", "title": "INVOLVES", "to": "Overweight and Obese Subjects With Type 2 Diabetes"}, {"arrows": "to", "from": "NCT01351675", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "Stable Dose Period"}, {"arrows": "to", "from": "NCT01351675", "label": "HAS_CRITERIA", "title": "HAS_CRITERIA", "to": "eGFR \u003e 60 ml/min/1.73 m2"}]);

                  nodeColors = {};
                  allNodes = nodes.get({ returnType: "Object" });
                  for (nodeId in allNodes) {
                    nodeColors[nodeId] = allNodes[nodeId].color;
                  }
                  allEdges = edges.get({ returnType: "Object" });
                  // adding nodes and edges to the graph
                  data = {nodes: nodes, edges: edges};

                  var options = {"nodes": {"font": {"size": 20, "face": "arial"}}, "edges": {"arrows": {"to": {"enabled": true}}, "color": {"inherit": true}, "smooth": {"enabled": true}}, "physics": {"enabled": true, "stabilization": {"iterations": 150}}};

                  


                  

                  network = new vis.Network(container, data, options);

                  

                  

                  


                  
                      network.on("stabilizationProgress", function(params) {
                          document.getElementById('loadingBar').removeAttribute("style");
                          var maxWidth = 496;
                          var minWidth = 20;
                          var widthFactor = params.iterations/params.total;
                          var width = Math.max(minWidth,maxWidth * widthFactor);
                          document.getElementById('bar').style.width = width + 'px';
                          document.getElementById('text').innerHTML = Math.round(widthFactor*100) + '%';
                      });
                      network.once("stabilizationIterationsDone", function() {
                          document.getElementById('text').innerHTML = '100%';
                          document.getElementById('bar').style.width = '496px';
                          document.getElementById('loadingBar').style.opacity = 0;
                          // really clean the dom element
                          setTimeout(function () {document.getElementById('loadingBar').style.display = 'none';}, 500);
                      });
                  

                  return network;

              }
              drawGraph();
        </script>
    </body>
</html>